Skip to main content Accessibility help

We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.

Close cookie message
×
Hostname: page-component-6bf8c574d5-9f2xs Total loading time: 0 Render date: 2025-03-09T16:02:42.496Z Has data issue: false hasContentIssue false

20 - Fractionated products

from Section 2 - Selection and testing

Published online by Cambridge University Press:  12 January 2010

By
Peter R. Foster  and
Carol Bienek
Edited by
John A. J. Barbara ,
Fiona A. M. Regan  and
Marcela Contreras
Peter R. Foster
Affiliation:
Protein Fractionation Centre, Scottish National Blood Transfusion Service, Edinburgh, UK
Carol Bienek
Affiliation:
Protein Frachianation Centre, Scotish National Blood Transfusion Service, Edinburgh, UK
John A. J. Barbara
Affiliation:
University of the West of England, Bristol
Fiona A. M. Regan
Affiliation:
HNSBT and Hammersmith Hospitals NHS Trust, London
Marcela Contreras
Affiliation:
University of the West of England, Bristol
Get access

Summary

Fractionated products are plasma proteins that have been extracted from pooled human plasma and manufactured into stable pharmaceuticals in dose forms suitable for clinical administration (Foster, 2005). The major categories of fractionated products are immunoglobulins for the treatment of disorders of immunity, the prevention of specific infections and the prevention of RhD immunization, albumin for volume and protein replacement and coagulation factors for haemostasis. The annual requirement for fractioned plasma products in the UK includes over 2000 kg of intravenous immunoglobulin (IGIV) for the treatment of more than 1800 patients with primary immune deficiency; 120,000 doses of anti-D immunoglobulin to prevent haemolytic disease of the newborn in about 65,000 pregnancies; over 5000 kg of albumin for tens of thousands of patients treated for burns, shock and major trauma. In addition, over 500,000 doses of factor VIII concentrate, recombinant or plasma-derived, are required to treat about 6000 people with haemophilia A. In the USA it is estimated that as many as 1 million patients are treated each year with products derived from human plasma, with over 400,000 recipients of albumin and more than 20,000 recipients of IGIV. Worldwide, some 25 million litres of human plasma are fractionated each year, providing over 500 metric tonnes of human protein for therapeutic use (see Table 20.1).

Blood-borne infections which exist naturally in the human population present a particular threat to recipients of fractionated products because each batch of product may be prepared from many thousands of donations and because some patients may be treated repeatedly throughout their lives, thereby considerably increasing their probability of exposure to a batch associated with an infected donation (Lynch et al., 1996).

Type
Chapter
Information
Transfusion Microbiology , pp. 259 - 304
Publisher: Cambridge University Press
Print publication year: 2008

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Adcock, W. L., MacGregor, A., Davies, J. R., et al. (1998a) Chromatographic removal and heat inactivation of hepatitis A virus during the manufacture of human albumin. Biotechnol Appl Biochem, 28, 85–94.Google Scholar
Adcock, W. L., MacGregor, A., Davies, J. R., et al. (1998b) Chromatographic removal and heat inactivation of hepatitis B virus during the manufacture of human albumin. Biotechnol Appl Biochem, 28, 169–78.Google Scholar
Addiego, J. E., Gomperts, E., Liu, S. L., et al. (1992) Treatment of haemophilia A with highly purified factor VIII concentrate prepared by anti-FVIIIC immunoaffinity chromatography. Thromb Haemost, 67, 19–27.Google ScholarPubMed
Aiuti, F., Carbonari, M., Scano, G., et al. (1986) Screening for antibodies to LAV/HTLV-III in recipients of immunoglobulin preparations. Lancet, i, 1091.Google Scholar
Allain, J.-P. (1984) Non-factor VIII related constituents in concentrates. Scand J Haematol, 33 (Suppl. 41), 173–80.CrossRefGoogle Scholar
Allen, J. G., Enerson, D. M., Barron, E. S. G., et al. (1954) Pooled plasma with little or no risk of homologous serum jaundice. JAMA, 154, 103–7.CrossRefGoogle ScholarPubMed
Alter, H. J. (2000) You'll wonder where the yellow went: a 30 year perspective on the near-eradication of post-transfusion hepatitis. Nat Med, 6, 1082–4.CrossRefGoogle Scholar
Alving, B., Tankersley, D. L., Mason, B. L., et al. (1980) Contact-activated factors: contaminants of immunoglobulin preparations with coagulant and vasoactive activities. J Lab Clin Med, 96, 334–6.Google Scholar
Anderson, H. D. and Gibson, S. T. (1957) Evaluation of the risk of transmitting hepatitis by the administration of dried fibrinogen (human) (a preliminary report). In Hepatitis Frontiers, eds Hartman, F. W., LoGrippo, G., Mateer, J. G. and Barron, J., pp. 287–295. London, J. and A. Churchill Ltd.Google Scholar
Anderson, H. D., McCall, K. B., Sgouris, J. T., et al. (1966) The clinical use of dried fibrinogen (human) and the risk of transmitting hepatitis by its administration. Transfusion, 6, 234–6.CrossRefGoogle Scholar
Andrewes, C. H. and Horstmann, D. M. (1949) The susceptibility of viruses to ethyl ether. J Gen Microbiol, 3, 292–7.CrossRefGoogle ScholarPubMed
Aronson, D. L. (1990) The development of the technology and capacity for the production of factor VIII for the treatment of hemophilia A. Transfusion, 30, 748–58.CrossRefGoogle ScholarPubMed
Australian Senate (2004) Hepatitis C and the blood supply in Australia. Report of the Community Affairs Reference Committee of the Australian Senate, June 2004. Canberra, The Senate.
Atrah, H. I., Crawford, R. J., Dow, B. C., et al. (1985) Safety of intravenous immunoglobulin treatment. J Clin Pathol, 38, 1192–3.CrossRefGoogle ScholarPubMed
Aygoren-Pursen, E. and Scharrer, I. (1997) A multicenter pharmacosurveillance study for the evaluation of the efficacy and safety of recombinant factor VIII in the treatment of patients with hemophilia A. German Kogenate Study Group. Thromb Haemost, 78, 1352–6.Google Scholar
Aymard, J. P., Janot, C., Chermann, J. C., et al. (1985) Prevalence of antibodies to lymphadenopathy-AIDS virus in French haemophiliacs. Vox Sang, 49, 161–3.Google ScholarPubMed
Azimi, P. H., Roberto, R. R., Guralnik, J., et al. (1986) Transfusion-acquired hepatitis A in a premature infant with secondary nosocomial spread in an intensive care nursery. Am J Dis Child, 140, 23–7.Google Scholar
Azzi, A., Ciappi, S., Zakvrzewska, K., et al. (1992) Human parvovirus B19 infection in hemophiliacs first infused with two high-purity, virally attenuated factor VIII concentrates. Am J Hematol, 39, 228–30.CrossRefGoogle ScholarPubMed
Azzi, A., Santis, R., Morfini, M., et al. (2001) TT virus contaminates first-generation recombinant factor VIII concentrates. Blood, 98, 2571–3.CrossRefGoogle ScholarPubMed
Barbara, J., Howell, D., Briggs, M., et al. (1982) Post-transfusion hepatitis A. Lancet, i, 738.CrossRefGoogle Scholar
Barker, L. F. and Murray, R. (1972) Relationship of virus dose to incubation time of clinical hepatitis and time of appearance of hepatitis-associated antigen. Am J Med Sci, 263, 27–33.CrossRefGoogle ScholarPubMed
Barré-Sinoussi, F., Chermann, J. C., Rey, F., et al. (1983) Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS). Science, 220, 868–71.CrossRefGoogle Scholar
Barrowcliffe, T. W. (1993) Inhibitor development and activated factor VIII in concentrates. Thromb Haemost, 70, 1065–6.Google ScholarPubMed
Corsi, Bartolomi O., Azzi, A., Morfini, M., et al. (1988) Human parvovirus infection in hemophiliacs first infused with treated clotting factor concentrates. J Med Virol, 25, 165–70.CrossRefGoogle Scholar
Barundun, S., Kistler, P., Jeunet, F., et al. (1962) Intravenous administration of human γ-globulin. Vox Sang, 7, 157–74.CrossRefGoogle Scholar
Bauman, P. A., Lawrence, L. A., Biesert, L., et al. (2006) Critical factors influencing prion inactivation by sodium hydroxide. Vox Sang, 91, 34–40.CrossRefGoogle ScholarPubMed
Becton, D., Manno, C., Green, D., et al. (1994) Viral safety of an affinity-purified coagulation factor IX concentrate (Alphanine SD). Blood, 84 (Suppl. 1), 198a.Google Scholar
Beeson, P. B. (1943) Jaundice occurring one to four months after transfusion of blood or plasma. Report of seven cases. JAMA, 121, 1332–4.CrossRefGoogle Scholar
Beeson, P. B., Chesney, G. and McFarlan, A. M. (1944) Hepatitis following injection of mumps convalescent plasma. Lancet, i, 814–15.CrossRefGoogle Scholar
Bennett, B., Dawson, A. A., Gibson, B. S., et al. (1993) Study of viral safety of Scottish National Blood Transfusion Service factor VIII/IX concentrate. Transfus Med, 3, 295–8.CrossRefGoogle Scholar
Benveniste, R. E., Ochs, H. D., Fischer, S. H., et al. (1986) Screening for antibodies to LAV/HTLV-III in recipients of immunoglobulin preparations. Lancet, i, 1091–2.Google Scholar
Berg, R., Bjorling, H., Berntsen, K., et al. (1972) Recovery of Australia antigen from human plasma products separated by a modified Cohn fractionation. Vox Sang, 22, 1–13.CrossRefGoogle ScholarPubMed
Berg, , , W., ten Cate, J. W., Breederveld, C., et al. (1986) Seroconversion to HTLV-III in haemophiliacs given heat treated factor VIII concentrate. Lancet, I, 803–4.CrossRefGoogle Scholar
Berger, A., Doerr, H. W., Scharrer, I., et al. (1997) Follow-up of four HIV-infected individuals after administration of hepatitis C virus and GBV-C/hepatitis G virus contaminated intravenous immunoglobulin: evidence for HCV but not for GBV-C/HGV transmission. J Med Virol, 53, 25–30.3.0.CO;2-S>CrossRefGoogle Scholar
Berntorp, E. (1996) Why prescribe highly purified factor VIII and IX concentrates. Vox Sang, 70, 61–8.CrossRefGoogle ScholarPubMed
Bidwell, E. (1955) The purification of bovine antihaemophilic globulin. Br J Haematol, 1, 35–45.CrossRefGoogle ScholarPubMed
Biesert, L. (1996) Virus validation studies of immunoglobulin preparations. Clin Exp Rheumatol, 14 (Suppl. 15), S47–S52.Google ScholarPubMed
Biesert, L. and Suhartono, H. (1998) Solvent/detergent treatment of human plasma – a very robust method for virus inactivation. Validated virus safety of OCTAPLAS. Vox Sang, 74 (Suppl. 1), 207–12.CrossRefGoogle ScholarPubMed
Biesert, L., Lemon, S., Suhartono, H., et al. (1995) Virus validation experiments on the production process of OCTAVI SDPlus. Blood Coagul Fibrinolysis, 6 (Suppl. 2), S48–54.CrossRefGoogle ScholarPubMed
Biggs, R. (1974) Supply of blood-clotting-factor VIII for treatment of haemophilia. Lancet, i, 1339.CrossRefGoogle Scholar
Biggs, R. (1977) Haemophilia treatment in the United Kingdom from 1969 to 1974. Br J Haematol, 35, 487–504.CrossRefGoogle ScholarPubMed
Biggs, R. and MacFarlane, R. G. (1957) Human Blood Coagulation and its Disorders, 2nd edn. Oxford, Blackwell Scientific Publications.Google Scholar
Biggs, R., Douglas, A. S., MacFarlane, R. G., et al. (1952) Christmas disease. A condition previously mistaken for haemophilia. BMJ, 2, 1378–82.CrossRefGoogle ScholarPubMed
Biggs, R., Bidwell, E., Handley, D. A., et al. (1961) The preparation and assay of a Christmas factor (factor IX) concentrate and its use in the treatment of two patients. Br J Haematol, 7, 349–64.CrossRefGoogle Scholar
Bird, A. G., Codd, A. A. and Collins, A. (1985) Haemophilia and AIDS. Lancet, i, 162–3.CrossRefGoogle Scholar
Biswas, R. M., Nedjar, S., Wilson, L. T., et al. (1994) The effect on the safety of intravenous immunoglobulin of testing plasma for antibody to hepatitis C. Transfusion, 34, 100–4.CrossRefGoogle ScholarPubMed
Bjöikander, J., Cunningham-Rundles, C., Lundin, P., et al. (1988) Intravenous immunoglobulin prophylax is causing liver damage in 16 of 77 patients with hypogammaglobulinemia or IgG subclass deficiency. Am J Med, 84, 107–11.CrossRefGoogle Scholar
Bjøro, K., Frøland, S. S., Yun, Z., et al. (1994) Hepatitis C infection in patients with primary hypogammaglobulinemia after treatment with contaminated immune globulin. New Engl J Med, 331, 1607–11.CrossRefGoogle ScholarPubMed
Blackburn, E. K. (1974) Treatment of haemophilia. Lancet, ii, 105.CrossRefGoogle Scholar
Blanchard, M. C., Stokes, J., Hampil, B., et al. (1948) Methods of protection against homologous serum hepatitis II. The inactivation of hepatitis SH with ultraviolet rays. J Am Med Assoc, 138, 341–3.CrossRefGoogle Scholar
Blombäck, B. and Blombäck, M. (1956) Purification of human and bovine fibrinogen. Arkiv Kemi, 10, 415–43.Google Scholar
Bloom, A. L., Forbes, C. D. and Rizza, C. R. (1985) HTLV-III, haemophilia and blood transfusion. BMJ, 290, 1901.CrossRefGoogle ScholarPubMed
Blumberg, B. S. (1964) Polymorphism of the serum proteins and the development of iso-precipitins in transfused patients. Bull N Y Acad Med, 40, 377–86.Google Scholar
Blumberg, B. S., Gerstley, B. J. S., Hungerford, D. A., et al. (1967) A serum antigen (Australia antigen) in Down's syndrome, leukaemia and hepatitis. Ann Intern Med, 66, 924–31.CrossRefGoogle ScholarPubMed
Blümel, J., Schmidt, I, Wilkommen, H., et al. (2002) Inactivation of parvovirus B19 during pasteurization of human serum albumin. Transfusion, 42, 1011–18.CrossRefGoogle ScholarPubMed
Boklan, B. F. (1971) Factor IX concentrate and viral hepatitis. Ann Intern Med, 74, 298.CrossRefGoogle Scholar
Bos, O. J., Sunye, D. G., Nieuweboer, C. E., et al. (1998) Virus validation of pH 4-treated immunoglobulin products produced by the Cohn fractionation process. Biologicals, 26, 267–76.CrossRefGoogle ScholarPubMed
Boschetti, N., Niederhauser, I., Kempf, C., et al. (2004) Different susceptibility of B19 virus and mice minute virus to low pH treatment. Transfusion, 44, 1079–86.CrossRefGoogle ScholarPubMed
Boychyn, M., Yim, S. S., Bulmer, M., et al. (2004) Performance prediction of industrial centrifuges using scale-down models. Bioprocess Biosyst Eng, 26, 385–91.CrossRefGoogle ScholarPubMed
Boyer, P. D., Lum, F. G., Ballou, G. A., et al. (1946) The combination of fatty acids and related compounds with serum albumin. I. Stabilization against heat denaturation. J Biol Chem, 162, 181–98.Google ScholarPubMed
Brackmann, H. H. and Egli, H. (1988) Acute hepatitis B infection after treatment with heat inactivated factor VIII concentrate. Lancet, ii, 967.CrossRefGoogle Scholar
Bradley, D. W. and Maynard, J. E. (1983) Non-A, non-B hepatitis: research progress and current perspectives. Developments in Biological Standardization, 54, pp. 463–73. In Viral Hepatitis: Standardization in Immunoprophylaxis of Infections by Hepatitis Viruses, eds Papaevangelan, G. and Hennessen, W.. Basel, Karger.Google Scholar
Bradley, W. H., Loutit, J. F. and Maunsell, K. (1944) An episode of ‘homologous serum jaundice’. BMJ, 2, 268–9.CrossRefGoogle Scholar
Breen, F. A. and Tullis, J. L. (1969) Prothrombin concentrates in treatment of Christmas disease and allied disorders. J Am Med Assoc, 208, 1848–52.CrossRefGoogle ScholarPubMed
Bremard-Ourcy, C., Courouce, A. M., Badillet, M., et al. (1986) Screening for antibodies to LAV/HTLV-III in recipients of immunoglobulin preparations. Lancet, i, 1090–1.CrossRefGoogle Scholar
Bresee, J. S., Mast, S. E., Coleman, P. J., et al. (1996) Hepatitis C virus infection associated with administration of intravenous immune globulin: a cohort study. J Am Med Assoc, 276, 1563–7.CrossRefGoogle ScholarPubMed
Brettler, D. B., Alter, H. J., Dienstag, J. L., et al. (1990) Prevalence of hepatitis C virus antibody in a cohort of hemophilia patients. Blood, 76, 254–6.Google Scholar
Brightman, I. J. and Korns, R. F. (1947) Homologous serum jaundice in recipients of pooled plasma. J Am Med Assoc, 135, 268–72.CrossRefGoogle ScholarPubMed
Brinkhous, K. M., Shanbrom, E., Roberts, H. R., et al. (1968) A new high-potency glycine-precipitated antihemophilic factor (AHF) concentrate. Treatment of classical hemophilia and hemophilia with inhibitors. J Am Med Assoc, 205, 613–17.CrossRefGoogle ScholarPubMed
British Pharmacopoeia (2005) Normal immunoglobulin. In British Pharmacopoeia, vol. III, pp. 2895–6. London, The Stationery Office.
Brown, P., Cervenakova, L. and McShane, L. M., et al. (1999) Further studies of blood infectivity in an experimental model of transmissible spongiform encephalopathy, with an explanation of why blood components do not transmit Creutzfeldt-Jacob disease in humans. Transfusion, 39, 1169–78.CrossRefGoogle Scholar
Brown, P., Rohwer, R. G., Dunstan, B. C., et al., (1998) The distribution of infectivity in blood components and plasma derivatives in experimental models of transmissible spongiform encephalopathy. Transfusion, 38, 810–16.CrossRefGoogle ScholarPubMed
Burnouf, T. (1993) Chromatographic removal of viruses from plasma derivatives. Developments in Biological Standardization, 81, 199–209.Google ScholarPubMed
Burnouf, T. and Radosevich, M. (2003) Nanofiltration of plasma-derived biopharmaceutical products. Haemophilia, 9, 24–37.CrossRefGoogle ScholarPubMed
Burnouf, T., Burnouf-Radosevich, M., Huart, J. J., et al. (1991) A highly purified factor VIII: C concentrate prepared from cryoprecipitate by ion exchange chromatography. Vox Sang, 60, 8–15.CrossRefGoogle ScholarPubMed
Burnouf, T., Michalski, C., Goudemand, M., et al. (1989) Properties of a highly purified human plasma factor IX: therapeutic concentrate prepared by conventional chromatography. Vox Sang, 57, 225–32.Google ScholarPubMed
Burnouf-Radosevich, M., Appourchaux, P., Huart, J. J., et al. (1994) Nanofiltration, a new specific virus elimination method applied to high-purity factor IX and factor IX concentrates. Vox Sang, 67, 132–8.CrossRefGoogle Scholar
Burrell, C. J., Black, S. H. and Ramsay, D. M. (1978) Antibody to hepatitis B surface antigen in haemophiliacs on long-term therapy with Scottish factor VIII. J Clin Pathol, 31, 309–12.CrossRefGoogle ScholarPubMed
Butt, A. A. (2006) Hepatitis C virus infection: the new global epidemic. Exp Rev Anti-Infect Ther, 3, 241–9.CrossRefGoogle Scholar
Chaves, Cabrera T., Marco, Simon M. A., Garcia, Gomollon F., et al. (1996) Hepatitis C following administration of intravenous immunoglobulin. Gastroenterologia y Hepatologia, 19, 305–8.Google Scholar
Cai, K., Gierman, T. M., Hotta, J. A., et al. (2005) Ensuring the biologic safety of plasma-derived therapeutic proteins. Biodrugs, 19, 79–96.CrossRefGoogle ScholarPubMed
Cai, K., Miller, J. L. C., Stenland, C. J., et al. (2002) Solvent-dependent precipitation of prion protein. Biochim Biophys Acta, 1597, 28–35.CrossRefGoogle ScholarPubMed
Callet-Fauquet, P., Giambattista, M., Draps, M. L., et al. (2004) An assay for parvovirus B19 neutralizing antibodies based on human hepatocarcinoma cell lines. Transfusion, 44, 1340–3.CrossRefGoogle Scholar
Cash, J. D., Dalton, R. G., Middleton, S., et al. (1975) Studies on the thrombogenicity of Scottish factor IX concentrates in dogs. Thromb Diath Haemorrh, 33, 632–9.Google ScholarPubMed
Centers for Disease Control (1974) Viral hepatitis-B associated with transfusion of plasma protein fraction. Morbidity and Mortality Weekly Report, 23 (11), 98.
Centers for Disease Control (1981a) Pneumocystis pneumonia – Los Angeles. Morbidity and Mortality Weekly Report, 30, 250–2.
Centers for Disease Control (1981b) Kaposi's sarcoma and Pneumocystis pneumonia among homosexual men – New York City and California. Morbidity and Mortality Weekly Report, 30, 305–8.
Centers for Disease Control (1982a) Pneumocystis carinii among persons with hemophilia A. Morbidity and Mortality Weekly Report, 31, 365–7.
Centers for Disease Control (1982b) Update on acquired immune deficiency syndrome (AIDS) among patients with hemophilia A. Morbidity and Mortality Weekly Report, 31, 644–6, 652.
Centers for Disease Control (1982c) Possible transfusion-associated acquired immune deficiency syndrome (AIDS) – California. Morbidity and Mortality Weekly Report, 31, 652–4.
Centers for Disease Control (1983) Prevention of acquired immune deficiency syndrome (AIDS): report of inter-agency recommendations. Morbidity and Mortality Weekly Report, 32, 101–3.
Centers for Disease Control (1984) Update: acquired immunodeficiency syndrome (AIDS) in persons with hemophilia. Morbidity and Mortality Weekly Report, 33, 589–91.
Centers for Disease Control (1986) Safety of therapeutic immune globulin preparations with respect to transmission of human T-lymphotropic virus type III/lymphadenopathy-associated virus infection. Morbidity and Mortality Weekly Report, 35, 231–3.
Centers for Disease Control (1994) Outbreak of hepatitis C associated with intravenous immunoglobulin administration – United States, October 1993–June 1994. Morbidity and Mortality Weekly Report, 43, 505–9.
Centers for Disease Control (1996) Hepatitis A among persons with hemophilia who received clotting factor concentrates – United States, September–December 1995. Morbidity and Mortality Weekly Report, 55, 841–4.
Centers for Disease Control (2006) The global HIV/AIDS pandemic, 2006. Morbidity and Mortality Weekly Report, 55, 841–4.
Cervenakova, L., Brown, P., Hammond, D. J., et al. (2002) Factor VIII and transmissible spongiform encephalopathy: the case for safety. Haemophilia, 8, 63–75.CrossRefGoogle ScholarPubMed
Chandra, S. and Brummelhuis, H. G. J. (1981) Prothrombin complex concentrates for clinical use. Vox Sang, 41, 257–73.CrossRefGoogle ScholarPubMed
Chandra, S., Groener, A. and Feldman, F. (2002) Effectiveness of alternative treatments for reducing potential viral contaminants from plasma-derived products. Throm Res, 105, 391–400.CrossRefGoogle ScholarPubMed
Charm, S. E. and Wong, B. L. (1974) An immunoadsorbent process for removing hepatitis antigen from blood and plasma. Biotechnol Bioeng, 16, 593–607.CrossRefGoogle ScholarPubMed
Cheinsong-Popov, R., Weiss, R. A., Dalgleish, A., et al. (1984) Prevalence of antibody to human T-lymphotropic virus type III in AIDS and AIDS-risk patients in Britain. Lancet, ii, 477–80.CrossRefGoogle Scholar
Chen, B. P., Rumi, M. G., Colombo, M., et al. (1999) TT virus is present in a high frequency of Italian hemophilic patients transfused with plasma-derived clotting factor concentrates. Blood, 94, 4333–6.Google Scholar
Cho, Y. K., Foley, B. T., Sung, H., et al. (2007) Molecular epidemiologic study of human immunodeficiency virus 1 outbreak in haemophiliacs B infected through clotting factor 9 after 1990. Vox Sang, 92, 113–20.CrossRefGoogle ScholarPubMed
Choo, Q.-L., Kuo, G., Weiner, A. J., et al. (1989) Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science, 244, 559–61.CrossRefGoogle ScholarPubMed
Christie, J. M., Healey, C. J., Watson, J., et al. (1997) Clinical outcome of hypogammaglobulinaemic patients following outbreak of acute hepatitis C: 2-year follow up. Clin Exp Immunol, 110, 4–8.CrossRefGoogle ScholarPubMed
Chudy, M., Budek, I., Keller-Stanislawski, B., et al. (1999) A new cluster of hepatitis A infection in hemophiliacs traced to a contaminated plasma pool. J Med Virol, 57, 91–9.3.0.CO;2-L>CrossRefGoogle ScholarPubMed
Coates, J. B. and McFetridge, E. M. (1964) The bovine and human albumin programmes. In Blood Programmes in World War II, eds. Coates, J. B. and McFetridge, E. M., pp. 325–57. Washington, Office of the Surgeon General.Google Scholar
Cockburn, W. C., Harrington, J. A., Zeitlin, R. A., et al. (1951) Homologous serum hepatitis and measles prophylaxis. A report to the Medical Research Council. BMJ, 2, 6–12.CrossRefGoogle ScholarPubMed
Cohen, B. (1995) Parvovirus B19: an expanding spectrum of disease. BMJ, 311, 1549–52.CrossRefGoogle Scholar
Cohn, E. J. (1948) The history of plasma fractionation. In Science in World War II. Advances in Military Medicine Made by American Investigators Working Under the Sponsorship of the Committee on Medical Research, Volume 1, eds. Andrus, E. C., Keefer, C. S., Bronke, D. W., et al., pp. 364–443. Boston, Little, Brown & Co.Google Scholar
Cohn, E. J., Gurd, F. R. N., Surgenor, D. M., et al. (1950) A system for the separation of the components of human blood: quantitative procedures for the separation of the protein components of human plasma. J Am Chem Soc, 72, 465–74.CrossRefGoogle Scholar
Cohn, R. J., Schwyzer, R.Field, S. P., et al. (1994) Acute hepatitis A in haemophiliacs. Thromb Haemost, 75, 785–6.Google Scholar
Cohn, E. J., Strong, C. E., Hughes, W. L., et al. (1946) Preparation and properties of serum and plasma proteins IV: a system for the separation into fractions of the protein and lipoprotein components of biological tissues and fluids. J Am Chem Soc, 68, 459–75.CrossRefGoogle Scholar
Colombo, M., Carnelli, V., Gazengel, C., et al. (1985) Transmission of non-A, non-B hepatitis by heat treated factor VIII concentrate. Lancet, ii, 1–4.CrossRefGoogle Scholar
Colvin, B. T. (1990) Prevention of hepatitis C infection in haemophiliacs. Lancet, 335, 1474.Google Scholar
Colvin, B. T., Rizza, C. R., Hill, F. G. H., et al. (1988) Effect of dry-heating of coagulation factor concentrates at 80 ℃ for 72 hours on transmission of non-A, non-B hepatitis. Lancet, ii, 814–16.Google Scholar
Committee for Medicinal Products for Human Use (2004a) Guideline on Assessing the Risk for Virus Transmission – New Chapter 6 of the Note for Guidance on Plasma-Derived Medicinal Products (CPMP/BWP/269/95). CPMP/BWP/5180/03. London, European Medicines Agency.
Committee for Medicinal Products for Human Use (2004b) Position Statement on Creutzfeldt-Jakob Disease and Plasma-Derived and Urine-Derived Medicinal Products. CPMP/BWP/2879/02/rev 1. London, European Medicines Agency.
Committee for Medicinal Products for Human Use (2004c) Guideline on the Investigation of Manufacturing Processes for Plasma-Derived Medicinal Products with Regard to vCJD Risk. CPMP/BWP/CPMP/5136/03. London, European Medicines Agency.
Committee for Medicinal Products for Human Use (2006) Guideline on the Clinical Investigation of Human Anti-D Immunoglobulin for Intravenous and/or Intramuscular Administration. CPMP/BPWG/575/99 rev.1. London, European Medicines Agency.
Committee for Proprietary Medicinal Products (1991) Validation of virus removal and inactivation procedures. Biologicals, 19, 247–51.CrossRef
Committee for Proprietary Medicinal Products (1992) Guidelines for medicinal products derived from human blood and plasma. Biologicals, 20, 159–64.CrossRef
Committee for Proprietary Medicinal Products (1995a) Note for Guidance on Validation of Analytical Methods: Definitions and Terminology. CPMP/ICH/381/95. London, European Agency for the Evaluation of Medicinal Products.
Committee for Proprietary Medicinal Products (1995b) Intramuscular Immunoglobulins: Nucleic Acid Amplification Tests for HCV RNA Detection. CPMP/117/95, annex 4. London, European Agency for the Evaluation of Medicinal Products.
Committee for Proprietary Medicinal Products (1996a) Note for Guidance on Virus Validation Studies: the Design, Contribution and Interpretation of Studies Validating the Inactivation and Removal of Viruses. CPMP/BWP/268/95 revised. London, European Agency for the Evaluation of Medicinal Products.
Committee for Proprietary Medicinal Products (1996b) Note for Guidance on Plasma-Derived Medicinal Products. CPMP/BWP/269/95. London, European Agency for the Evaluation of Medicinal Products.
Committee for Proprietary Medicinal Products (1997) Note for Guidance on Quality of Biotechnological Products: Viral Safety Evaluation of Biotechnology Products Derived from Cell Lines of Human or Animal Origin. CPMP/ICH/295/95. London, European Agency for the Evaluation of Medicinal Products.
Committee for Proprietary Medicinal Products (1998) The Introduction of Nucleic Acid Amplification Technology (NAT) for the Detection of Hepatitis C Virus RNA in Plasma Pools. CPMP/BWP/390/97. London, European Agency for the Evaluation of Medicinal Products.
Committee for Proprietary Medicinal Products (2001) Note for Guidance on Plasma-Derived Medicinal Products. CPMP/BWP/269/95 rev. 3. London, European Agency for the Evaluation of Medicinal Products.
Cossart, Y. E., Field, A. M., Cant, B., et al. (1975) Parvovirus-like particles in human sera. Lancet, i, 72–3.CrossRefGoogle Scholar
Counts, R. B. (1977) Serum transaminase and HBsAb antibody in hemophiliacs treated exclusively with cryoprecipitate. In Unsolved Therapeutic Problems in Hemophilia, eds. Fratantoni, J. C. and Aronson, D. L., pp. 71–3. Washington, US, Department of Health, Education, and Welfare, DHEW publication no. (NIH) 77–1089.Google Scholar
Craske, J., Dilling, N. and Stern, D. (1975) An outbreak of hepatitis associated with intravenous injection of factor-VIII concentrate. Lancet, ii, 221–3.CrossRefGoogle Scholar
Craske, J., Kirk, P., Cohen, B., et al. (1978) Commercial factor VIII associated hepatitis, 1974–75, in the United Kingdom: a retrospective survey. J Hyg (Lond), 80, 327–36.CrossRefGoogle ScholarPubMed
Crewdson, J. (2002) Science Fictions. Boston, Little, Brown and Company.Google Scholar
Cronberg, S., Belfrage, S. and Nilsson, I. M. (1963) Fibrinogen-transmitted hepatitis. Lancet, i, 967–9.CrossRefGoogle Scholar
Crovari, P., Flora, S. and Castagna, M. (1975) Distribution of hepatitis B surface antigen in plasma fractions extracted by the Cohn method. Giornale di Igiene e Medicina Preventiva, 16, 3–12.Google Scholar
Cumming, R. A., Davies, S. H., Ellis, D., et al. (1965) Red cell banking and the production of a factor VIII concentrate. Vox Sang, 10, 687–99.CrossRefGoogle Scholar
Cunningham, C. J. (1980) Production of human immunoglobulin anti-D (RhO) for intravenous administration for a national Rh prophylaxis programme. Biochem Soc Trans, 8, 178–9.CrossRefGoogle ScholarPubMed
Cuthbert, R. J., Ludlam, C. A., Brookes, E., et al. (1988) Efficacy of heat treatment of factor VIII concentrate. Vox Sang, 54, 199–200.CrossRefGoogle ScholarPubMed
Cuthbertson, B., Perry, R. J., Foster, P. R., et al. (1987a) The viral safety of intravenous immunoglobulin. J Infect, 15, 125–33.CrossRefGoogle Scholar
Cuthbertson, B., Rennie, J. G., Aw, D., et al. (1987b) Safety of albumin preparations manufactured from plasma not tested for HIV antibody. Lancet, ii, 41.CrossRefGoogle Scholar
Cutter Biological (1978) Koate Antihemophilic Factor (Human) for Haemophilia A. Product Insert, October 1978. Berkeley, California, Cutter Laboratories Inc.
Dane, D. S., Cameron, C. H. and Briggs, M. (1970) Virus-like particles in serum of patients with Australia-antigen-associated hepatitis. Lancet, i, 695–8.CrossRefGoogle Scholar
Darnell, M. E. and Taylor, D. R. (2006) Evaluation of inactivation methods for severe acute respiratory syndrome coronavirus in noncellular blood products. Transfusion, 46, 1770–7.CrossRefGoogle ScholarPubMed
Filippi, F., Castelli, R., Cicardi, M., et al. (1998) Transmission of hepatitis G virus in patients with angioedema treated with steam-heated plasma concentrates of C1 inhibitor. Transfusion, 38, 302–11.CrossRefGoogle ScholarPubMed
Del Duca, V. and Eppes, R. B. (1966) Hepatitis transmitted by anti-hemophilic globulin. N Eng Med, 275, 965–6.Google Scholar
Department of Health (1998) Committee on Safety of Medicines Completes Review of Blood Products, press release no. 98/102. London, Department of Health.
Department of Health (1999) The Good Laboratory Practice Regulations 1999. UK Department of Health, Statutory Instruments 1999 No. 3106. London, The Stationery Office Limited.
Department of Health (2002) Department of Health Secures Guaranteed Long-Term Supplies of Plasma for NHS Patients, press release no. 2002/0524. London, Department of Health.
Dichtelmuller, H., Rudnick, D., Breuer, B., et al. (1993) Validation of virus inactivation and removal for the manufacturing procedure of two immunoglobulins and a 5% serum protein solution treated with beta-propiolactone. Biologicals, 21, 259–68.CrossRefGoogle Scholar
Dichtelmuller, H., Rudnick, D., Rinscheid, V., et al. (1998) Removal of viruses by Asahi 35nm nanofiltration of IVIG. In Proceedings of Planova® Workshop, Oslo, 27 June 1998, pp. 27–37. Tokyo, Asahi Chemical Industry Co. Ltd.Google Scholar
Didisheim, P., Loeb, J., Blatrix, C., et al. (1959) Preparation of a human plasma fraction rich in prothrombin, proconvertin, Stuart factor, and PCT and a study of its activity and toxicity in rabbits and man. J Lab Clin Med, 53, 322–30.Google Scholar
Dietrich, S. L., Mosley, J. W., Lusher, J. M., et al. (1990) Transmission of human immunodeficiency virus type 1 by dry-heated clotting factor concentrates. Vox Sang, 59, 129–35.Google ScholarPubMed
Dike, G. W. R., Bidwell, E. and Rizza, C. R. (1972) The preparation and clinical use of a new concentrate containing factor IX, prothrombin and factor X and of a separate concentrate containing factor VII. Br J Haematol, 22, 469–90.CrossRefGoogle ScholarPubMed
DiLeo, A. J. and Allegrezza, A. E. (1991) Validatable virus removal from protein solutions. Nature, 351, 420–21.CrossRefGoogle ScholarPubMed
Dittmann, S., Roggendorf, M., Dürkop, J., et al. (1991) Long-term persistence of hepatitis C virus antibodies in a single source outbreak. J Hepatol, 13, 323–7.CrossRefGoogle Scholar
Dormandy, K. M. (1974) Blood fractions for haemophilia. Lancet, ii, 155.CrossRefGoogle Scholar
Drake, M. E., Hampil, B., Pennell, R. B., et al. (1952) Effect of nitrogen mustard on virus of serum hepatitis in whole blood. Proceedings of the Society of Experimental Biology and Medicine, 80, 310–13.CrossRefGoogle ScholarPubMed
Echevarria, J. M., Leon, P., Domingo, C. J., et al. (1996) Laboratory diagnosis and molecular epidemiology of an outbreak of hepatitis C virus infection among recipients of human intravenous immunoglobulin in Spain. Transfusion, 36, 725–30.CrossRefGoogle ScholarPubMed
Editorial (1947) Homologous serum hepatitis. Lancet, ii, 691–2.
Edsall, J. T. (1984) Stabilization of serum albumin to heat, and inactivation of the hepatitis virus. Vox Sang, 46, 338–40.CrossRefGoogle ScholarPubMed
Edwards, C. A., Piet, M. P., Chin, S., et al. (1987) Tri-n-butyl phosphate/detergent treatment of licensed therapeutic and experimental blood derivatives. Vox Sang, 52, 53–9.CrossRefGoogle ScholarPubMed
Eibl, J., Barret, N., Hämmerle, T., et al. (1996) Nanofiltration of immunoglobulin with 35-nm filters fails to remove substantial amounts of HCV. Biologicals, 24, 285–7.CrossRefGoogle ScholarPubMed
Einarsson, M., Kaplan, L., Nordenfelt, E., et al. (1981) Removal of hepatitis B virus from a concentrate of coagulation factors II, VII, IX and X by hydrophobic interaction chromatography. J Virol Methods, 3, 213–28.CrossRefGoogle Scholar
Einarsson, M., Prince, A. M. and Brotman, B. (1985) Removal of non-A, non-B hepatitis virus from a concentrate of the coagulation factors II, VII, IX and X by hydrophobic interaction chromatography. Scand J Infect Dis, 17, 141–6.CrossRefGoogle Scholar
Emile-Weil, P. (1906) Etude du sang chez les hémophiles. Bulletins et Mémoires de la Société Médicale des Hôpitaux de Paris, 23, 1001–18.Google Scholar
Enders, J. F. (1944) Chemical, clinical, and immunological studies on the products of human plasma fractionation. X. The concentrations of certain antibodies in globulin fractions derived from human blood plasma. J Clin Invest, 23, 510–30.CrossRefGoogle ScholarPubMed
Enoki, C., Higashi, S., Oohata, M., et al. (2002) A case of acute erythroblastic anemia due to infection with human parvovirus B19 after coronary bypass grafting. Kyobu Geka, 55, 116–9.Google Scholar
Esteban, J. I., Esteban, R., Viladomui, L., et al. (1989) Hepatitis C virus antibodies among risk groups in Spain. Lancet, ii, 294–7.CrossRefGoogle Scholar
Ettingshausen, C. E. and Kreuz, W. (2006) Recombinant vs. plasma-derived products, especially those with intact VWF, regarding inhibitor development. Haemophilia, 12 (Suppl. 6), 102–6.CrossRefGoogle ScholarPubMed
European Pharmacopoeia (2004) Validation of nucleic acid amplification techniques (NAT) for the detection of hepatitis C virus (HCV) RNA in plasma pools: guidelines. In European Pharmacopoeia, 5th edn, vol. 1, pp. 176–177. Strasburg, Council of Europe.
Evatt, B. L. (2006) The tragic history of AIDS in the hemophilia population 1982–1984. J Thromb Haemost, 4, 2295–301.CrossRefGoogle ScholarPubMed
Evatt, B. L., Gomperts, E. D., McDougal, J. S., et al. (1985) Coincidental appearance of LAV/HTLV-III antibodies in hemophiliacs and the onset of the AIDS epidemic. N Eng J Med, 312, 483–6.CrossRefGoogle ScholarPubMed
Evensen, S. A., Rollag, H. and Glomstein, A. (1995) Hepatitis C virus seroconversion in a haemophiliac treated exclusively with solvent/detergent-treated clotting factor concentrate. Eur J Clin Microbiol Infect Dis, 14, 631–2.CrossRefGoogle Scholar
Fanning, L. J. (2002) The Irish paradigm on the natural progression of hepatitis C virus infection: an investigation in a homogeneous patient population infected with HCV 1b (review). Int J Mol Med, 9, 179–84.Google Scholar
Farshid, M., Mitchell, F., Biswas, R., et al. (1997) Prevalence of hepa-titis G virus in hepatitis C virus (HCV)-infected patients and in HCV-contaminated intravenous immunoglobulin products. J Vir Hepat, 4, 415–19.CrossRefGoogle Scholar
Feinstone, S. M., Kapikian, A. Z. and Purcell, R. H. (1973) Hepatitis A: detection by immune electron microscopy of a virus-like antigen associated with acute illness. Science, 182, 1026–8.CrossRefGoogle Scholar
Feinstone, S. M., Kapikian, A. Z., Purcell, ., et al. (1975) Transfusion-associated hepatitis not due to viral hepatitis type A or B. N Eng J Med, 292, 767–70.CrossRefGoogle ScholarPubMed
Feinstone, S. M., Mihalik, K. B., Kamimura, T., et al. (1983) Inactivation of hepatitis B virus and non-A, non-B hepatitis by chloroform. Infect Immun, 41, 816–21.Google ScholarPubMed
Feissley, R. (1924) Recherches sur la pathogénie at la thérapeutique des états hémophiliques. Schweizerische Medizinische Wochenschrift, 55, 81–4.Google Scholar
Felding, P., Nilsson, I. M., Hansson, B. G., et al. (1985) Absence of antibodies to LAV/HTLV-III in haemophiliacs treated with heat-treated factor VIII concentrate of American origin. Lancet, ii, 832–3.CrossRefGoogle Scholar
Feldman, F., Klekamp, M. S., Hrinda, M. E., et al. (1989) Stabilization of Biologicals and Pharmaceutical Products during Thermal Inactivation of Viral and Bacterial Contaminants. US Patent, no. 4876241.Google Scholar
Feldman, P. and Roberts, P. (1998) Virus-filtration of factor IX – an approach to process validation. In Proceedings of Planova® Workshop, Oslo, 27 June 1998, pp. 47–55. Tokyo, Asahi Chemical Industry Co. Ltd.Google Scholar
Fernandes, P. M. (1997) Deposition in JKB vs. Armour Pharmaceutical Corporation, et al., 25 January 1997. Vallejo, California, Doucette Legal Services.Google Scholar
Fernandes, P. M. and Lundblad, J. L. (1984) Pasteurised Therapeutically Active Protein Compositions. US Patent, no. 440679.Google Scholar
Findlay, G. M., MacCallum, F. O. and Murgatroyd, F. (1939) Observations bearing on aetiology of infective hepatitis (so-called catarrhal jaundice). Trans R Soc Trop Med Hyg, 32, 575–86.CrossRefGoogle Scholar
Finlay, T. A. (1997) Report of the Tribunal of Inquiry into the Blood Transfusion Service Board. Dublin, Government Publications.Google Scholar
Finlayson, J. S. and Tankersley, D. L. (1990) Anti-HCV screening and plasma fractionation: the case against. Lancet, 335, 1274–5.CrossRefGoogle ScholarPubMed
Fiore, J. W., Olson, W. P. and Holst, S. L. (1980) Depth filtration. In Methods of Plasma Protein Fractionation, ed. Curling, J. M., London, Academic Press. pp. 239–68.Google Scholar
Fitzpatrick, J. and Kennedy, C. C. (1969) Serum hepatitis in a haemophiliac. BMJ, 4 (5678), 299.CrossRefGoogle Scholar
Flan, B. and Aubin, J. T. (2005) Evaluation de l'efficacité des procédés de purification des protéines plasmatique à éliminer les agents transmissible non-conventionnels. Virologie, 9, 545–56.Google Scholar
Forbes, C. D. and Prentice, C. R. M. (1977) Mortality in haemophilia – a United Kingdom survey. In Unsolved Therapeutic Problems in Hemophilia, eds. Fratantoni, J. C. and Aronson, D. L., pp. 15–22. WashingtonUS Department of Health, Education, and Welfare, DHEW publication no. (NIH) 77–1089.Google Scholar
Foster, P. R. (1994) Protein precipitation. In Engineering Processes for Bioseparation, ed. Weatherley, L. R.. Oxford, Butterworth-Heinemann, pp. 73–109.Google Scholar
Foster, P. R. (1999) Assessment of the potential of plasma fractionation processes to remove causative agents of transmissible spongiform encephalopathy. Transfus Med, 9, 3–14.CrossRefGoogle ScholarPubMed
Foster, P. R. (2000) Prions and blood products. Annals of Medicine, 32, 501–13.CrossRefGoogle ScholarPubMed
Foster, P. R. (2005) Fractionation, plasma. In The Kirk-Othmer Encyclopedia of Chemical Technology. 5th edn, volume 12, ed. Seidel, A.. New York, John Wiley & Sons, Inc. pp. 128–59.Google Scholar
Foster, P. R. (2006) Plasma products. In Creutzfeldt-Jakob Disease: Managing the Risk of Transmission by Blood, Plasma, and Tissues, ed. Turner, M. L.. Bethesda, Maryland, AABB Press. pp. 187–213.Google Scholar
Foster, P. R., Cuthbertson, B., McIntosh, R. V., et al. (1997a) Safer clotting factor concentrates. In Hemophilia, eds Forbes, C. D., Aledort, L. and Madhok, R., pp. 307–32. London, Chapman & Hall Medical.Google Scholar
Foster, P. R., Cuthbertson, B., Perry, R. J., et al. (1988b) Coagulation factor VIII concentrates and the marketplace. Lancet, ii, 43.Google Scholar
Foster, P. R., Dickson, I. H., Macleod, A. J., et al. (1983a) Zinc fractionation of cryoprecipitate. Thromb Haemost, 50, 117.Google Scholar
Foster, P. R., Dickson, I. H., McQuillan, T. A., et al. (1983b) Factor VIII stability during the manufacture of a clinical concentrate. Thromb Haemost, 50, 117.Google Scholar
Foster, P. R., Dickson, I. H., McQuillan, T. A., et al. (1988a) Studies on the stability of VIII:C during the manufacture of a factor VIII concentrate for clinical use. Vox Sang, 55, 81–9.CrossRefGoogle Scholar
Foster, P. R., Griffin, B. D., Bienek, C., et al. (2004) Distribution of a bovine spongiform encephalopathy-derived agent over ion exchange chromatography in the preparation of concentrates of fibrinogen and factor VIII. Vox Sang, 86, 92–9.CrossRefGoogle ScholarPubMed
Foster, P. R., McIntosh, R. V. and Welch, A. G. (1995) Hepatitis C infection from anti-D immunoglobulin. Lancet, 346, 372.CrossRefGoogle ScholarPubMed
Foster, P. R., Patterson, M. R., Dickson, A. J., et al. (1980b) Intermediate purity factor VIII concentrate: changes in antigen and coagulant activity during production. Br J Haematol, 46, 334.Google Scholar
Foster, P. R., Patterson, M. R., Johnson, A. J., et al. (1980a) Thrombogenicity of factor IX concentrates and polyethylene glycol processing. Thrombosis Research, 17, 273–9.CrossRefGoogle Scholar
Foster, P. R., Welch, A. G., Cuthbertson, B., et al. (1997b) Immunoglobulin for intravenous use. Transfus Med, 7, 67–9.CrossRefGoogle Scholar
Foster, P. R., Welch, A. G., McLean, C., et al. (2000) Studies on the removal of abnormal prion protein by processes used in the manufacture of human plasma products. Vox Sang, 78, 86–95.CrossRefGoogle ScholarPubMed
Fox, J. P., Manso, C., Penna, H. A., et al. (1942) Observations on the occurrence of icterus in Brazil following vaccination against yellow fever. Am J Hyg, 36, 68–116.Google Scholar
Funk, M., Ebener, U. and Kreuz, W. (1993) Immune status of HIV and HCV negative haemophiliacs treated with intermediate-purity factor VIII concentrates. Lancet, 342, 933–4.CrossRefGoogle ScholarPubMed
Gaboulaud, V., Parquet, A., Tahiri, C., et al. (2002) Prevalence of IgG antibodies to human parvovirus B19 in haemophilia children treated with recombinant factor (F) VIII only or with at least one plasma-derived FVIII or FIX concentrate: results from the French haemophilia cohort. Br J Haematol, 116, 383–9.CrossRefGoogle ScholarPubMed
Gallo, R. C., Popovic, M. and Sarngadharan, M. G. (1985) Serological detection of antibodies to HTLV-III in sera of patients with AIDS and pre-AIDS conditions. US Patent no. 4 520 113.
Gallo, R. C., Salahuddin, S. Z., Popovic, M., et al. (1984) Frequent detection and isolation of cytopathic retroviruses (HTLV-III) from patients with AIDS or at risk from AIDS. Science, 224, 500–3.CrossRefGoogle ScholarPubMed
Galpin, S. A., Karayiannis, P., Middleton, S. M., et al. (1984) The removal of hepatitis B virus from factor VIII concentrates by fractionation on ethylene maleic anhydride polyelectrolyte. J Med Virol, 14, 229–33.CrossRefGoogle ScholarPubMed
Garcia, T., Lopez, A., Quintana, M., et al. (1996) HGV in coagulation factor concentrates. Lancet, 348, 1032.CrossRefGoogle Scholar
Gazengel, C., Torcher, M. F., Boneu, B., et al. (1988) Viral safety of solvent/detergent treated factor VIII concentrate. Results of a French multicenter study. In Proceedings of 18th International Congress of World Federation of Hemophilia, eds Papaevangelon, G. and Hennessen, W., p. 59. Madrid, World Federation of Hemophilia.Google Scholar
Gedye, R. (1993) German AIDS scandal infects Europe. BMJ, 307, 1229.Google ScholarPubMed
Gellis, S. S., Neefe, J. R., Stokes, J., et al. (1948) Chemical, clinical and immunological studies on the products of human plasma fractionation. XXXVI. Inactivation of the virus of homologous serum hepatitis in solutions of normal human serum albumin by means of heat. J Clin Invest, 27, 239–44.CrossRefGoogle Scholar
Gerety, R. J. (1985) Safety aspects. Discussion. In Plasma Fractionation and Blood Transfusion, eds. Sibinga, C. Th. Smit and Das, P. C., p. 181. Boston, Kluwer Academic Publishers.CrossRefGoogle Scholar
Gerety, R. J. and Aronson, D. L. (1982) Plasma derivatives and viral hepatitis. Transfusion, 22, 347–51.CrossRefGoogle ScholarPubMed
Gerolami, V., Halfon, P., Chambost, H., et al. (1997) Prevalence of hepatitis G virus RNA in a population of French haemophiliacs. Br J Haematol, 99, 209–14.CrossRefGoogle Scholar
Gerolami, V., Halfon, P., Chambost, H., et al. (1998) Transfusion transmitted virus. Lancet, 352, 1309.CrossRefGoogle ScholarPubMed
Gerritzen, A., Schneweis, K. E., Brackmann, H. H., et al. (1992b) Acute hepatitis A in haemophiliacs. Lancet, 340, 1231–2.CrossRefGoogle Scholar
Gerritzen, A., Scholt, B., Kaiser, R., et al. (1992a) Acute hepatitis C in haemophiliacs due to ‘virus inactivated’ clotting factor concentrates. Thromb Haemost, 68, 781.Google Scholar
Gilligan, K. J., Pizzi, V. F., Stenland, C., et al. (2002) The use of size exclusion composite membrane to remove TSE infectious particles from a model protein solution filtration. Poster PS 1020EN00. Bedford, MA, Millipore Publications.Google Scholar
Glied, S. (1999) The circulation of the blood. AIDS, blood, and the economics of information. In Blood Feuds. AIDS, Blood, and the Politics of Medical Disaster, eds. Feldman, E. A. and Bayer, R., pp. 322–347. New York, Oxford University Press.Google Scholar
Gocke, D. J., Raska, K., Pollack, W., et al. (1986) HTLV-III antibody in commercial immunoglobulin. Lancet, i, 37–8.CrossRefGoogle Scholar
Gomperts, E. D. (1994) HCV and Gammagard in France. Lancet, 344, 201.CrossRefGoogle ScholarPubMed
Gomperts, E. D. (1996) Gammagard and reported hepatitis C virus episodes. Clin Therap, 18 (Suppl. B), 3–8.CrossRefGoogle ScholarPubMed
Gonzaga, A. L. and Bonecker, C. (1990) Follow-up of hemophiliacs using solvent/detergent treated FVIII and FIX concentrates. In Proceedings of 19th International Congress of the World Federation of Hemophilia, eds. Brown, F. and Lubiniecki, A. S., p. 25. Washington, World Federation of Hemophilia.Google Scholar
Goudemand, J., Laurian, Y. and Calvez, T. (2006b) Risk of inhibitors in haemophilia and the type of factor replacement. Curr Opin Hematol, 13, 316–22.CrossRefGoogle Scholar
Goudemand, J., Rothschild, C., Demiguel, V., et al. (2006a) Influence of the type of factor VIII concentrate on the incidence of factor VIII inhibitors in previously untreated patients with severe hemophilia A. Blood, 107, 46–51.CrossRefGoogle Scholar
Gregori, L., Maring, J. A., MacAuley, C., et al. (2004) Partitioning of TSE infectivity during ethanol fractionation of human plasma. Biologicals, 32, 1–10.CrossRefGoogle ScholarPubMed
Griffin, M. (1991) Ultrapure plasma factor VIII produced by anti-FVIIIC immunoaffinity chromatography and solvent/detergent viral inactivation. Characterisation of the Method M process and Hemofil M antihemophilic factor (human). Ann Hematol, 63, 131–7.CrossRefGoogle Scholar
Grosse-Bley, A., Eis-Hubinger, A. M., Kaiser, R., et al. (1994) Serological and virological markers of human parvovirus B19 infection in sera of haemophiliacs. Thromb Haemost, 72, 503–7.Google Scholar
Grossman, C. M. and Saward, E. W. (1946) Homologous serum jaundice following the administration of commercial pooled plasma. A report of eight cases including one fatality. N Eng J Med, 234, 181–3.CrossRefGoogle ScholarPubMed
Guérois, C.Rothschild, C., Laurian, Y., et al. (1993) Incidence of inhibitors specific for factor VIII. Inhibitor development in severe haemophilia patients treated with only one brand of highly purified plasma-derived concentrate. Thromb and Haemost, 73, 215–8.Google Scholar
Gunson, H. H. and Rawlinson, V. I. (1991) Screening of blood donations for HIV-1 antibody: 1985–1991. Communicable Disease Report Review, 1 (no. 13), R144–6.Google ScholarPubMed
Hamalainen, E., Suomela, H. and Ukkonen, P. (1992) Virus inactivation during intravenous immunoglobulin production. Vox Sang, 63, 6–11.CrossRefGoogle ScholarPubMed
Hamamoto, Y., Harada, S., Kobayashi, K., et al. (1989) A novel method for removal of human immunodeficiency virus: filtration with porous polymeric membranes. Vox Sang, 56, 230–6.CrossRefGoogle ScholarPubMed
Hanley, J. P., Jarvis, L. M., Hayes, P. C., et al. (1998) Patterns of hepatitis G viraemia and liver disease in haemophiliacs previously exposed to non-virus inactivated coagulation factor concentrates. Thromb Haemost, 79, 291–5.Google Scholar
Harasawa, R. and Sasaki, T. (1995) Sequence analysis of the 5' untranslated region of pestivirus RNA demonstrated in interferons for human use. Biologicals, 23, 263–9.CrossRefGoogle ScholarPubMed
Harris, R. B., Johnson, A. J., Semar, M., et al. (1979) Freedom from transmission of hepatitis-B of gamma-globulin and heat-inactivated plasma protein fraction prepared from contaminated human plasma by fractionation with solid-phase polyelectrolytes. Vox Sang, 36, 129–36.CrossRefGoogle ScholarPubMed
Hart, H., Hart, W. G., Crossley, J., et al. (1994b) Effect of terminal (dry) heat treatment on non-enveloped viruses in coagulation factor concentrates. Vox Sang, 67, 345–50.CrossRefGoogle Scholar
Hart, H., Hart, W. G. and Foster, P. R. (1995) Virus inactivation in intravenous immunoglobulin: a comparison with SD treatment of factor VIII. Transfus Med, 5 (Suppl. 1), 41.Google Scholar
Hart, H., Jones, A., Cubie, H., et al. (1994a) Distribution of hepatitis A antibody over a process for the preparation of a high-purity factor VIII concentrate. Vox Sang, 67 (Suppl. 1), 51–5.CrossRefGoogle Scholar
Hart, H., McIntosh, R. V. and Foster, P. R. (1996) Safety of coagulation factor concentrates: reducing the infectious bioburden. Haemophilia, 2 (Suppl. 1), 23.Google Scholar
Hartman, W. H., Kelly, A. R. and LoGrippo, G. A. (1955) Four-year study concerning the inactivation of viruses in blood and plasma. Gastroenterology, 28, 244–56.Google ScholarPubMed
Hartman, F. W., LoGrippo, G. A. and Kelly, A. R. (1956) Procedure for sterilisation of plasma using combinations of ultra violet iradiating and beta-propiolactone. Federation Proceedings, 15, 518.Google Scholar
Hayakawa, F., Imada, K., Towatari, M., et al. (2002) Life-threatening human parvovirus B19 infection transmitted by intravenous immune globulin. Br J Haematol, 118, 1187–9.CrossRefGoogle ScholarPubMed
Healey, C. J., Sabharwal, ., McOmish, F., et al. (1996) Outbreak of acute hepatitis C following the use of anti-HCV screened intravenous immunoglobulin therapy. Gastroenterology, 110, 1120–6.CrossRefGoogle ScholarPubMed
Hedlund, K. (1973) Hepatitis B antigen: removal from protein solutions in a recognizable form by an insoluble lipophilic matrix of silicic acid. Life Sci, 13, 1491–7.CrossRefGoogle Scholar
Heimburger, N., Schwinn, H., Gratz, P., et al. (1981a) A factor VIII concentrate highly purified and heated in solution. Haemostasis, 10 (Suppl. 1), 204.Google Scholar
Heimburger, N., Schwinn, H., Gratz, P., et al. (1981b) Factor VIII concentrate highly purified and heated in solution. Arzneimittel-Forschung, 31, 619–22.Google Scholar
Heimburger, N., Schwinn, H. and Mauler, R. (1980) Factor VIII concentrate – now free from hepatitis risk: progress in the treatment of haemophilia. Die gelben Hefte, 4, 165–74.Google Scholar
Heimburger, N., Wormsbacher, W. and Kumpe, G. (1986) Process for the Production of a Pasteurized Isoagglutinin-free Factor VIII Preparation from a Cryoprecipitate. European Patent no. EP0173242.
Heldebrandt, C. M., Gomperts, E. D.Kasper, C. K., et al. (1985) Evaluation of two viral inactivation methods for the preparation of safer factor VIII and factor IX concentrates, Transfusion, 25, 510–5.CrossRefGoogle Scholar
Hellerstein, L. J. and Deykin, D. (1971) Hepatitis after Konyne administration. N Eng J Med, 284, 1039–40.Google ScholarPubMed
Henin, Y., Maréchal, V., Barré-Sinoussi, F., et al. (1988) Inactivation and partition of human immunodeficiency virus during Kistler and Nitschmann fractionation of human blood plasma. Vox Sang, 54, 78–83.CrossRefGoogle ScholarPubMed
Herring, S. W., Abildgaard, C., Shitanishi, K. T., et al. (1993) Human coagulation factor IX: assessment of thrombogenicity in animal models and viral safety. J Lab Clin Med, 121, 394–405.Google ScholarPubMed
Hershgold, E. J., Pool, J. G. and Pappenhagen, A. R. (1966) The potent antihemophilic globulin concentrate derived from a cold insoluble fraction of human plasma: characterization and further data on preparation and clinical trial. J Lab Clin Med, 67, 23–32.Google ScholarPubMed
Heystek, J., Brummelhuis, H. G. J. and Krijnen, H. W. (1973) Contributions to the optimal use of human blood. II. The large-scale preparation of prothrombin complex. A comparison between two methods using the anion exchangers DEAE-cellulose DE52 and DEAE-Sephadex A-50. Vox Sang, 25, 113–23.CrossRefGoogle Scholar
Hile, J. P. (1978) Fibrinogen (human) revocation of licenses. Federal Register, 43, 1131–2.Google Scholar
Hilfenhaus, J. and Nowak, T. (1994) Inactivation of hepatitis A virus by pasteurization and elimination of picornaviruses during manufacture of factor VIII concentrate. Vox Sang, 67 (Suppl. 1), 62–6.CrossRefGoogle ScholarPubMed
Hilfenhaus, J., Geiger, H., Lemp, J., et al. (1987) A strategy for testing established human plasma protein manufacturing procedures for their ability to inactivate or eliminate human immunodeficiency virus. J Biol Stand, 15, 251–63.CrossRefGoogle ScholarPubMed
Hilfenhaus, J. W., Gregersen, J. P., Mehdi, S., et al. (1990) Inactivation of HIV-1 and HIV-2 by various manufacturing procedures for human plasma proteins. Cancer Detec Preven, 14, 369–75.Google ScholarPubMed
Hilfenhaus, J., Herrmann, A., Mauler, R., et al. (1986) Inactivation of the AIDS-causing retrovirus and other human viruses in antihemophilic plasma protein preparations by pasteurisation. Vox Sang, 50, 208–11.CrossRefGoogle Scholar
Hino, M., Ishiko, O., Honda, K. I., et al. (2000) Transmission of symptomatic parvovirus B19 infection by fibrin sealant used during surgery. Br J Haematol, 108, 194–5.CrossRefGoogle ScholarPubMed
Hino, M., Yamamura, R., Nishiki, S., et al. (1999) Human parvovirus B19-induced aplastic crisis in a patient treated with fibrin sealant. Japanese J Clin Hematol, 40, 145–9.Google Scholar
Hoag, M. S., Johnson, F. F., Robinson, J. A., et al. (1969) Treatment of hemophilla B with a new clotting-factor concentrate. N Eng J Med, 280, 581–6.CrossRefGoogle Scholar
Hollinger, F. B., Doland, G.,Thomas, W., et al. (1984) Reduction in risk of hepatitis transmission by heat-treatment of a human factor VIII concentrate. J Infect Dis, 150, 250–62.CrossRefGoogle ScholarPubMed
Hollinger, F. B., Khan, N. C., Oefinger, P. E., et al. (1983) Post-transfusion hepatitis type A. J Am Med Assoc, 250, 2313–17.CrossRefGoogle Scholar
Hoofnagle, J. H. and Barker, L. F. (1976) Hepatitis B virus and albumin products. In Proceedings of the Workshop on Albumin, eds. Sgouris, J. T. and René, A., pp. 305–14. Washington, Department of Health, Education, and Welfare, DHEW Publication No. (NIH) 76–925.Google Scholar
Hoofnagle, J. H. and Waggoner, J. G. (1980) Hepatitis A and B virus markers in immune serum globulin. Gastroenterology, 78, 259–63.Google Scholar
Hoofnagle, J. H., Aronson, D. and Roberts, H. (1975) Serological evidence for hepatitis B virus infection in patients with hemophilia B. Thrombosis et Diathesis Haemorrhagica, 33, 606–9.Google Scholar
Hoofnagle, J. H., Gerety, R. J., Thiel, J., et al. (1976) The prevalence of hepatitis B surface antigen in commercially prepared plasma products. J Lab Clin Med, 88, 102–13.Google ScholarPubMed
Hooper, J. A. (1997) Production and properties of intravenous immunoglobulins. In Intravenous Immunoglobulins in Clinical Practice, eds Lee, M. L. and Strand, V., pp. 37–55. New York, Marcel Dekker Inc.Google Scholar
Hooper, J. A., Alpern, M. and Mankarious, S. (1988) Immunoglobulin manufacturing procedures. In Immunoglobulins, eds Krijnen, H. W., Strengers, P. F. W. and Aken, W. G., pp. 361–80. Amsterdam, Central Laboratory of the Netherlands Red Cross.Google Scholar
Hoppe, H. H., Krebs, H. J., Mester, T., et al. (1967) Production of anti-Rh gamma globulin for preventive immunisation. Munchener Medizinische Wochenschrift, 109, 1749–52.Google Scholar
Hoppe, H. H., Mester, T., Hennig, W., et al. (1973) Prevention of Rh-immunization. Modified production of IgG anti-Rh for intravenous application by ion exchange chromatography (IEC). Vox Sang, 25, 308–16.CrossRefGoogle Scholar
Horowitz, B. (1989) Investigations into the application of tri-n-butyl phosphate/detergent mixtures to blood derivatives. In Virus Inactivation in Plasma Products, ed. Morgenthaler, J. J., pp. 83–96. Basel, Karger.Google ScholarPubMed
Horowitz, B. (1991) Potential accumulation of tri-n-butyl phosphate in solvent-detergent virus-inactivated plasma products (reply). Transfusion, 31, 871.Google Scholar
Horowitz, B. and Ben-Hur, E. (2000) Efforts in minimizing risk of viral transmission through viral inactivation. Ann Med, 32, 475–84.CrossRefGoogle ScholarPubMed
Horowitz, B., Lazo, A., Grossberg, H., et al. (1998) Virus inactivation by solvent/detergent treatment and the manufacture of SD-plasma. Vox Sang, 74 (Suppl. 1), 203–6.CrossRefGoogle ScholarPubMed
Horowitz, B., Wiebe, M. E., Lippin, A., et al. (1985) Inactivation of viruses in labile blood derivatives. I. Disruption of lipid-enveloped viruses by tri-n-butyl phosphate detergent combinations. Transfusion, 25, 516–22.CrossRefGoogle ScholarPubMed
Horowitz, M. S., Rooks, C., Horowitz, B., et al. (1988) Virus safety of solvent/detergent-treated antihemophilic factor concentrate in previously untreated patients. Lancet, ii, 186.CrossRefGoogle Scholar
Horzinek, M. C. (1981) Non-Arthropod-Borne Togaviruses. London, Academic Press.Google Scholar
Hrindra, M. E., Feldman, F. and Schrieber, A. B. (1990) Preclinical characterisation of a new pasteurised monoclonal antibody purified factor VIIIC. Semin Hematol, 27 (2, Suppl. 2), 19–24.Google Scholar
Hrindra, M. E., Huang, C., Tarr, G. C., et al. (1991) Preclinical studies of a monoclonal antibody-purified factor IX, Mononine™. Semin Hematol, 28 (3, Suppl. 6), 6–14.Google Scholar
Hsia, D.Y-Y., Kennell, J. H. and Gellis, S. S. (1953) Homologous serum-hepatitis following the use of Fraction IV prepared from postpartum plasma. A report of four cases. Am J Med Sci, 226, 261–4.CrossRefGoogle ScholarPubMed
Hubbard, A. R., Weller, L. J. and Bevan, S. A. (2002) A survey of one-stage and chromogenic potencies in therapeutic factor VIII. Br J Haematol, 117, 247–8.CrossRefGoogle ScholarPubMed
Hyland (1975) Hemofil AHF Products, Product Insert. December 1975. Costa Mesa, California, Hyland Division Travenol Laboratories Inc.
Ikeda, Y., Hirano, T. and Murakami, H. (1986) Screening for antibodies to LAV/HTLV-III in recipients of immunoglobulin preparations. Lancet, i, 1092.Google Scholar
Imbach, P., Perret, B. A., Babington, R., et al. (1991) Safety of intravenous immunoglobulin preparations: a prospective multicenter study to exclude the risk of non-A, non-B hepatitis. Vox Sang, 61, 240–3.CrossRefGoogle ScholarPubMed
Ingram, G. I. C. (1974) Blood fractions for treatment of haemophilia. Lancet, ii, 56–7.CrossRefGoogle Scholar
Ireland, T., Lutz, H., Siwak, M., et al. (2004) Viral filtration of plasma-derived human IgG: a case study using Viresolve NFP. BioPharm International, 17 (11), 38–44.Google Scholar
Iwarson, S., Einarsson, M., Smallwood, L., et al. (1987) Chromatographic removal of hepatitis B virus from a factor IX concentrate. Experimental studies in chimpanzees. Transfusion, 27, 171–3.CrossRefGoogle ScholarPubMed
Jacobson, I. M., Dienstag, J. L., Werner, B. G., et al. (1985) Epidemiology and clinical impact of hepatitis D virus (delta) infection. Hepatology, 5, 188–91.CrossRefGoogle ScholarPubMed
Jacquemot, C., Cuche, C., Dormont, D., et al. (2005) High incidence of scrapie induced by repeated injection of sub-infectious prion doses. J Virol, 79, 8904–8.CrossRefGoogle Scholar
Jakubik, J. J., Vicik, S. M., Tannatt, M. M., et al. (2004) West Nile virus inactivation by the solvent/detergent steps of the second and third generation manufacturing processes from B-domain deleted recombinant factor VIII. Haemophilia, 10, 69–74.CrossRefGoogle ScholarPubMed
Janeway, C. A. (1948) Clinical use of blood derivatives. J Am Med Assoc, 138, 859–65.CrossRefGoogle ScholarPubMed
Jantsch-Plunger, V., Beck, G. and Maurer, W. (1995) PCR detection of a low viral load in a prothrombin complex concentrate that transmitted hepatitis B virus. Vox Sang, 69, 352–4.CrossRefGoogle Scholar
Jason, J., McDougal, J. S., Holman, R. C., et al. (1985) Human T-lymphotropic retrovirus type III/lymphadenopathy-associated virus antibody. Association with hemophiliacs' immune status and blood component usage. J Am Med Assoc, 253, 3409–15.CrossRefGoogle ScholarPubMed
Jason, J. M. (1984) HTLV-I/II and HTLV-III seroprevalence in blood product recipients. Presentation at The Ninth Annual Symposium on Blood Transfusion, Gronigen, The Netherlands, 2 November 1984.
John, T. J., Ninan, G. T., Rajagopalan, M. S., et al. (1979) Epidemic hepatitis B caused by commercial immunoglobulin. Lancet, i, 1074.CrossRefGoogle Scholar
Johnson, A. J., MacDonald, V. E., Semar, M., et al. (1978) Preparation of the major plasma fractions by solid-phase polyelectrolytes. J L Clin Med, 92, 194–210.Google ScholarPubMed
Johnson, A. J., Newman, J., Howell, M. B., et al. (1967) Purification of antihemophilic factor (AHF) for clinical and experimental use. Thrombosis Diathesis Haemorrhagica, 26 (Suppl.), 377–81.Google ScholarPubMed
Johnson, A. J., Semar, M., Newman, J., et al. (1976) Removal of hepatitis B surface antigen (HBsAg) from plasma fractions. J Lab Clin Med, 88, 91–101.Google ScholarPubMed
Johnson, Z., Thomson, L., Tobin, A.et al. (1995) An outbreak of hepatitis A among Irish haemophiliacs. International Journal of Epidemology, 24, 821–8.CrossRefGoogle ScholarPubMed
Johnston, A., MacGregor, A., Borovec, S., et al. (2000) Inactivation and clearance of viruses during the manufacture of high purity factor IX. Biologicals, 28, 129–6.CrossRefGoogle ScholarPubMed
Jones, P. (1974) Blood fractions for haemophilia. Lancet, ii, 155.Google Scholar
Jordan, R. T. and Kempe, L. L. (1957) Virus inactivation with gamma radiation from cobalt60. In Hepatitis Frontiers, eds Hartman, F. W., LoGrippo, G. A., Mateer, J. G. and Barron, J., pp. 343–54. London, J. & A. Churchill Ltd.Google Scholar
Josic, D., Hoffer, L., Buchacher, A., et al. (2000) Manufacturing of a prothrombin complex concentrate aiming at low thrombogenicity. Thromb Res, 100, 433–41.CrossRefGoogle ScholarPubMed
Kappeler, A., Lutz-Wallace, C., Sapp, T., et al. (1996) Detection of bovine polyomavirus contamination in fetal bovine sera and modified live viral vaccines using using polymerase chain reaction. Biologicals, 24, 131–5.CrossRefGoogle ScholarPubMed
Karcher, H. (1991) German haemophilic patients infected with HIV. BMJ, 303, 1352–3.Google Scholar
Kasermann, F., Kempf, C. and Boschetti, N. (2004) Strengths and limitations of the model virus concept. PDA J Pharm Sci Technol, 58, 244–9.Google ScholarPubMed
Kasper, C. K. and Kipnis, S. A. (1972) Hepatitis and clotting-factor concentrates. J Am Med Assoc, 221, 510.CrossRefGoogle ScholarPubMed
Kasper, C. K., Lusher, J. M., Silberstein, C. E., et al. (1993) Recent evolution of clotting factor concentrates for hemophilia A and B. Transfusion, 33, 422–34.CrossRefGoogle ScholarPubMed
Kawamura, M., Sawafuji, M., Watanabe, M., et al. (2002) Frequency of transmission of human parvovirus B19 infection by fibrin sealant used during thoracic surgery. Ann Thorac Surg, 73, 1098–1100.CrossRefGoogle ScholarPubMed
Kekwick, R. A. and MacKay, M. E. (1954) The Separation of Protein Fractions from Human Plasma with Ether. Medical Research Council Special Report Series No. 286. London, Her Majesty's Stationery Office.
Kekwick, R. A. and Wolf, P. (1957) A concentrate of antihemophilic factor; its use in six cases of haemophilia. Lancet, i, 647–50.CrossRefGoogle Scholar
Kempf, C., Jentsch, P., Barré-Sinoussi, F., et al. (1991) Inactivation of human immunodeficiency virus (HIV) by low pH and pepsin. J Acquir Immune Defic Syndr, 4, 828–30.Google Scholar
Kenny-Walsh, E. (1999) Clinical outcomes after hepatitis C infection from contaminated anti-D immune globulin. Irish hepatology research group. N Eng J Med, 340, 1228–33.CrossRefGoogle ScholarPubMed
Kernoff, P. B. A., Miller, E. J., Savidge, G. F., et al. (1987) Reduced risk of non-A, non-B hepatitis after a first exposure to ‘wet heated’ factor VIII concentrate. Br J Haematol, 67, 207–11.CrossRefGoogle ScholarPubMed
Kingdon, H. S. (1970) Hepatitis after Konyne. Ann Intern Med, 73, 656–7.CrossRefGoogle ScholarPubMed
Kirchebner, Ch., Sölder, E. and Schönitzer, D. (1994) Prevention of rhesus incompatibility and viral safety. Infusionsther Transfusionsmed, 21, 281–3.Google ScholarPubMed
Kistler, P. and Nitschmann, H. (1962) Large-scale production of human plasma fractions. Eight years' experience with the alcohol fractionation procedure of Nitschmann, Kistler and Lergier. Vox Sang, 7, 414–24.CrossRefGoogle Scholar
Kleim, J. P., Bailly, E., Schneweis, K. E., et al. (1990) Acute HIV-1 infection in patients with haemophilia B treated with β-propiolactone-UV-inactivated clotting factor. Thromb Haemost, 64, 336–7.Google ScholarPubMed
Kreil, T. R. (2004) West Nile virus: recent experience with the model virus approach. Dev Biol (Basel), 118, 101–5.Google ScholarPubMed
Kreil, T. R., Berting, A., Kistner, O., et al. (2003) West Nile virus and the safety of plasma derivatives: verification of high safety margins, and the validity of predictions based on model virus data. Transfusion, 43, 1023–28.CrossRefGoogle ScholarPubMed
Kreil, T. R., Wieser, A., Berting, A., et al. (2006) Removal of small nonenveloped viruses by antibody-enhanced nanofiltration during the manufacture of plasma derivatives. Transfusion, 46, 1143–51.CrossRefGoogle ScholarPubMed
Kreuz, W., Auerswald, G., Brachmann, C., et al. (1992) Prevention of hepatitis C virus infection in children with haemophilia A and B von Willebrand's disease. Thromb Haemost, 67, 184.Google Scholar
Kumar, J., Shaver, M. J. and Abul-Ezz, S. (2005) Long-term remission of recurrent parvovirus-B associated anemia in a renal transplant recipient induced by treatment with immunoglobulin and positive seroconversion. Transpl Infect Dis, 7, 30–33.CrossRefGoogle Scholar
Kupfer, B., Oldenburg, J., Brackmann, H. H., et al. (1995) Beta-propiolactone UV inactivated clotting factor concentrate is the source of HIV-infection of 8 hemophilia B patients: confirmed. Thromb Haemost, 74, 1386–7.Google ScholarPubMed
Kuo, G., Choo, Q. L., Alter, H. J., et al. (1989) An assay for circulating antibodies to a major etiologic virus of human non-A, non-B hepatitis. Science, 244, 362–4.CrossRefGoogle ScholarPubMed
Lane, R. S. (1983) Non-A, non-B hepatitis from intravenous immunoglobulin. Lancet, ii, 974–5.CrossRefGoogle Scholar
Lane, S. (1840) Successful transfusion of blood. Lancet, i, 185–8.CrossRefGoogle Scholar
Laub, R., Giambattista, M. D., Fondu, P., et al. (1997) Restricted epitope specificity for factor VIII inhibitors which appeared in previously treated haemophiliacs after infusion with OCTAVI SD plus. Thromb Haemost, 77 (Suppl.), 590.Google Scholar
Laurian, Y., Dussaix, E., Parquet, A., et al. (1994) Transmission of human parvovirus B19 by plasma derived factor VIII concentrates. Nouvelle Revue Française Hématologie, 36, 449–53.Google ScholarPubMed
Leary, T. P., Muerhoff, A. S., Simmonds, J. N., et al. (1996) Sequence and genomic organization of GBV-C a novel member of the Flaviviridae associated with human non-A-E hepatitis. J Med Virol, 48, 60–2.3.0.CO;2-A>CrossRefGoogle ScholarPubMed
Lederman, M. M., Ratnoff, O. D., Evatt, B. L., et al. (1985) Acquisition of antibody to lymphadenopathy-associated virus in patients with classical hemophilia (factor VIII deficiency). Ann Intern Med, 102, 753–7.CrossRefGoogle Scholar
Lee, C. A. (1995) Hepatitis C virus and haemophilia: the natural history of HCV in haemophilia patients. Haemophilia, 1 (Suppl. 4), 8–12.Google Scholar
Lee, C. A., Kernoff, P. B., Karayiannis, P., et al. (1985) Interaction between hepatotropic viruses in patients with haemophilia. J Hepatol, 1, 379–84.CrossRefGoogle Scholar
Lee, D. C., Stenland, C. J., Hartwell, R. C., et al. (2000) Monitoring plasma processing steps with a sensitive Western blot assay for the detection of the prion protein. J Virol Methods, 84, 77–89.CrossRefGoogle ScholarPubMed
Lee, D. C., Stenland, C. J., Miller, J. L. C., et al. (2001) A direct relationship between partitioning of the pathogenic prion protein and transmissible spongiform encephalopathy infectivity during purification of plasma proteins. Transfusion, 41, 49–55.CrossRefGoogle ScholarPubMed
Lee, M. L., Kingdon, H. S., Hooper, J., et al. (1987) Safety of an intravenous immunoglobulin preparation: lack of seroconversion for human immunodeficiency virus. Clin Thera, 9, 300–3.Google ScholarPubMed
Leen, C. L. S., Yap, P. L., Neil, G., et al. (1986) Serum ALT levels in patients with primary hypogammaglobulinaemia receiving replacement therapy with intravenous immunoglobulin or fresh frozen plasma. Vox Sang, 50, 26–32.CrossRefGoogle ScholarPubMed
Lefrere, J. J., Loiseau, P., Martinot-Peignoux, M., et al. (1996) Infection by hepatitis C virus through contaminated intravenous immune globulin: results of a prospective national inquiry in France. Transfusion, 36, 394–7.CrossRefGoogle ScholarPubMed
Lehane, D., Kwantes, C. M. S., Upward, M. G. and Thomson, D. R. (1949) Homologous serum jaundice. BMJ, 2, 572–4.CrossRefGoogle ScholarPubMed
Lesses, M. F. and Hamolsky, M. W. (1951) Epidemic of homologous serum hepatitis apparently caused by human thrombin. J Am Med Assoc, 147, 727–30.CrossRefGoogle ScholarPubMed
Levene, C. and Blumberg, B. S. (1969) Additional specificities of Australia antigen and the possible identification of hepatitis carriers. Nature, 221, 195–6.CrossRefGoogle ScholarPubMed
Lever, A. M. L., Webster, A. D. B., Brown, D., et al. (1984) Non-A, non-B hepatitis occurring in agammaglobulinaemic patients after intravenous immunoglobulin. Lancet, ii, 1062–4.CrossRefGoogle Scholar
Levy, J. A., Mitra, G. A., Wong, M. F., et al. (1985) Inactivation by wet and dry heat of AIDS-associated retroviruses during factor VIII purification from plasma. Lancet, i, 1456–7.CrossRefGoogle Scholar
Lewis, J. H. (1970) Hemophilia, hepatitis and HAA. Vox Sanguinis, 19, 406–9.Google ScholarPubMed
Lewis, J. H., Maxwell, N. G. and Brandon, J. M. (1974) Jaundice and hepatitis B antigen/antibody in hemophilia. Transfusion, 14, 203–11.CrossRefGoogle ScholarPubMed
Lindsay, A. (2002) Report of the Tribunal of Inquiry into the Infection with HIV and Hepatitis C of Persons with Haemophilia and Related Matters. Dublin, Government of Ireland Publications.
Linnen, L., Wages, J., Zhangekeck, Z. Y., et al. (1996) Molecular cloning and disease association of hepatitis G virus. A transfusion transmissible agent. Science, 271, 505–8.CrossRefGoogle ScholarPubMed
Littlewood, J. D., Dawes, J., Smith, J. K., et al. (1987) Studies on the effect of heat treatment on the thrombogenicity of factor IX concentrates in dogs. Br J Haematol, 65, 463–8.CrossRefGoogle ScholarPubMed
Llewelyn, C. A., Hewitt, P. E., Knight, R. S. G., et al. (2004) Possible transmission of variant Creutzfeldt-Jakob disease by blood transfusion. Lancet, 363, 417–21.CrossRefGoogle ScholarPubMed
LoGrippo, G. A. and Rupe, C. E. (1957) Chemical sterilization of whole blood and plasma with beta-propiolactone. In Hepatitis Frontiers, eds. Hartman, F. W., LoGrippo, G. A., Mateer, J. G. and Barron, J., pp. 371–85. London, J. & A. Churchill Ltd.Google Scholar
Louie, R. E., Galloway, C. J., Dumas, M. L., et al. (1994) Inactivation of hepatitis C virus in low pH intravenous immunoglobulin. Biologicals, 22, 13–9.CrossRefGoogle ScholarPubMed
Lubetsky, A., Hoffman, R., Zimlichman, R., et al. (2004) Efficacy and safety of a prothrombin complex concentrate (Octaplex®) for rapid reversal of oral anticoagulation. Thromb Res, 113, 371–8.CrossRefGoogle Scholar
Ludlam, C. A. (1997) New-variant Creutzfeldt-Jakob disease and treatment of haemophilia. Lancet, 350, 1704.CrossRefGoogle ScholarPubMed
Ludlam, C. A., Chapman, D., Cohen, B., et al. (1989) Antibodies to hepatitis C virus in haemophilia. Lancet, ii, 560–1.Google Scholar
Ludlam, C. A., Tucker, J., Steel, C. M., et al. (1985) Human T-lymphotropic virus type III (HTLV-III) infection in seronegative haemophiliacs after transfusion of factor VIII. Lancet, ii, 233–6.CrossRefGoogle Scholar
Lürman, A. (1885) Eine icterusepidemic. Berliner Klinischhe Wochenschrift, 22, 20–3.Google Scholar
Lynch, T., Weinstein, M. J., Tankersley, D. L., et al. (1996) Considerations of pool size in the manufacture of plasma derivatives. Transfusion, 36, 770–5.CrossRefGoogle ScholarPubMed
Machin, S. J., McVerry, B. A., Cheinsong-Popov, R., et al. (1985) Seroconversion for HTLV-III since 1980 in British haemophiliacs. Lancet, i, 336.CrossRefGoogle Scholar
MacLeod, A. J., Cuthbertson, B. and Foster, P. R. (1984) Pasteurisation of factor VIII and factor IX concentrates. In Abstracts of 18th Congress of the International Society of Blood Transfusion, p. 34. Basel, Karger.Google Scholar
MacNalty, A. S. (1938) Acute infective jaundice and administration of measles serum. In On the State of the Public Health. Annual Report of the Chief Medical Officer of the Ministry of Health for the Year 1937, pp. 38–9. London, His Majesty's Stationery Office.Google Scholar
Madhok, R., Melbye, M., Lowe, G. D., et al. (1985) HTLV-III antibody in sequential plasma samples: from haemophiliacs 1974–84. Lancet, i, 524–5.CrossRefGoogle Scholar
Mainwaring, R. L. and Brueckner, G. G. (1966) Fibrinogen-transmitted hepatitis. A controlled study. J Am Med Assoc, 195, 437–41.CrossRefGoogle ScholarPubMed
Mannucci, P. M. (1974) Blood fractions for haemophilia. Lancet, ii, 584.CrossRefGoogle Scholar
Mannucci, P. M. (1992) Outbreak of hepatitis A among Italian patients with haemophilia. Lancet, 339, 819.CrossRefGoogle ScholarPubMed
Mannucci, P. M. (1993) Clinical evaluation of viral safety of coagulation factor VIII and IX concentrates. Vox Sang, 64, 197–203.CrossRefGoogle ScholarPubMed
Mannucci, P. M. (2003) AIDS, hepatitis and hemophilia in the 1980s: memoirs from an insider. J Thromb Haemost, 1, 2065–69.CrossRefGoogle ScholarPubMed
Mannucci, P. M. and Colombo, M. (1988) Virucidal treatment of clotting factor concentrates. Lancet, ii, 782–5.CrossRefGoogle Scholar
Mannucci, P. M. and Colombo, M. (1989) Revision of the protocol recommended for studies of safety from hepatitis of clotting factor concentrates. Thromb Haemost, 61, 532–4.Google ScholarPubMed
Mannucci, P. M., Capitanio, A., Del Ninno, E., et al. (1975) Asymptomatic liver disease in haemophiliacs. J Clin Pathol, 28, 620–4.CrossRefGoogle ScholarPubMed
Mannucci, P. M., Gdovin, S., Gringeri, A., et al. (1994) Transmission of hepatitis A to patients with haemophilia by factor VIII concentrates treated with organic solvent and detergent to inactivate viruses. Ann Intern Med, 120, 1–7.CrossRefGoogle ScholarPubMed
Mannucci, P. M., Schimpf, K., Brettler, D. B., et al. (1990) Low-risk for hepatitis in hemophiliacs given a high-purity, pasteurized factor VIII concentrate. Ann Intern Med, 113, 24–32.CrossRefGoogle Scholar
Mariani, G., Dipaolantonio, T., Baklaya, R., et al. (1991) Prospective hepatitis C safety evaluation of a high purity solvent detergent treated FVIII concentrate. Blood, 78 (Suppl. 1), 55a.Google Scholar
Mariani, G., Dipaolantonio, T., Baklaya, R., et al. (1993) Prospective study of the evaluation of hepatitis C virus infectivity in a high-purity, solvent/detergent-treated factor VIII concentrate: parallel evaluation of other markers for lipid-enveloped and non-lipid-enveloped virus. Transfusion, 33, 814–8.CrossRefGoogle Scholar
Matsui, H., Sugimoto, M., Tsuji, S., et al. (1999) Transient hypoplastic anemia caused by a primary human parvovirus B19 infection in a previously untreated patient with hemophilia transfused with a plasma-derived, monoclonal antibody-purified factor VIII concentrate. J Pediatr Hematol Oncol, 21, 74–6.CrossRefGoogle Scholar
Mauser, E., Marjolen, D., Zaaijer, H., et al. (1998) Hepatitis G virus RNA and E2 antibodies in Dutch haemophiliac patients. Blood, 92, 2164–6.Google Scholar
Mauser-Bunschoten, E. P., Varon, D., Savidge, G. F., et al. (1993) Effects of chronic use of monoclate, pasterized in patients with haemophilia A previously unexposed to factor VIII concentrate or other blood products. Blood, 82 (Suppl. 7), 153.Google Scholar
Maycock, W. d'A. (1964) Transmission of hepatitis by blood and blood products. Proceedings of Royal Society of Medicine, 57, 1077–80.Google ScholarPubMed
Maycock, W. d'A., Evans, S., Vallet, L., et al. (1963) Further experience with a concentrate containing human antihaemophilic factor. Br J Haemato, 9, 215–35.CrossRefGoogle Scholar
McCall, K. B., Gordon, F. H., Bloom, F. C., et al. (1957) Methods for the preparation and ultraviolet irradiation of human fibrinogen for intravenous use. J Am Pharma Assoc, 46, 295–8.CrossRefGoogle ScholarPubMed
McDougal, J. S., Martin, L. S., Court, S. P., et al. (1985) Thermal inactivation of the acquired immunodeficiency syndrome virus T-cell lymphotropic virus-III/lymphadenopathy-associated virus, with special reference to antihemophilic factor. J Clin Invest, 76, 875–7.CrossRefGoogle Scholar
McGrath, K. M., Thomas, K. B., Herrington, R. W., et al. (1985) Use of heat-treated clotting-factor concentrates in patients with haemophilia and a high exposure to HTLV-III. Med J Aust, 143, 11–3.Google Scholar
McIntosh, R. V., Dickson, A. J., Smith, D., et al. (1990) Freezing and thawing plasma. In Cryopreservation and Low Temperature Biology in Blood Transfusion, eds Sibinga, C. Th. Smit, Das, P. C. and Meryman, H. T., pp. 11–24. Norwell, MA, Kluwer Academic Publishers.CrossRefGoogle Scholar
McIntosh, R. V., Docherty, N., Fleming, D., et al. (1987) A high yield factor VIII concentrate suitable for advanced heat treatment. Thromb Haemost, 58, 306.Google Scholar
McIntosh, R. V., Rogers, P., Latto, D., et al. (1996) Safety of coagulation factor concentrates: validation of equipment for virus inactivation. Haemophilia, 2 (Suppl. 1), 23.Google Scholar
McGhee, S. A., Kaska, B., Liebhaber, M.,et al. (2005) Persistent parvovirus-associated chronic fatigue treated with high dose intravenous immunoglobulin. Pediatr Infect Dis J, 24, 272–4.CrossRefGoogle ScholarPubMed
McMillan, C. W., Diamond, C. L., and Surgenor, D. M. (1961) Treatment of classic hemophilia: the use of fibrinogen rich in factor VIII for hemorrhage and for surgery. N Eng J Med, 265, 224–30.CrossRefGoogle Scholar
Meer, J.der, Daenen, S., Imhoff, G. W., et al. (1986) Absence of seroconversion for HTLV-III in haemophiliacs intensively treated with heat treated factor VIII concentrates. British Medical Journal (Clinical Research Edition), 292, 1049.CrossRefGoogle Scholar
Meisel, H., Reip, A., Faltus, B., et al. (1995) Transmission of hepatitis C virus to children and husbands by women infected with contaminated anti-D immunoglobulin. Lancet, 345, 1209–11.CrossRefGoogle ScholarPubMed
Melbye, M., Biggar, R. J., Chermann, J. C., et al. (1984) High prevalence of lymphadenopathy virus (LAV) in European haemophiliacs. Lancet, ii, 40–1.CrossRefGoogle Scholar
Michalski, C., Bal, F., Burnouf, T.,et al. (1988) Large-scale production and properties of a solvent-detergent-treated factor IX concentrate from human plasma. Vox Sang, 55, 202–10.CrossRefGoogle ScholarPubMed
Middleton, S. M., Bennett, I. H. and Smith, J. K. (1973) A therapeutic concentrate of coagulation factors II, IX and X from citrated, factor VIII-depleted plasma. Vox Sang, 24, 441–56.Google Scholar
Ministry of Health (1943) Homologous serum jaundice. Memorandum prepared by Medical Officers of the Ministry of Health. Lancet, i, 83–8.
Minot, G. R. and Taylor, F. H. L. (1947) Hemophilia: the clinical use of antihemophilic globulin. Ann Intern Med, 26, 363–7.Google ScholarPubMed
Minot, G. R., Davidson, C. S., Lewis, J. H., et al. (1945) The coagulation defect in hemophilia: the effect, in hemophilia, of the parenteral administration of a fraction of the plasma globulins rich in fibrinogen. J Clin Invest, 24, 704–7.CrossRefGoogle Scholar
Mitra, G., Dobkin, M. B., Wong, M. F., et al. (1989) Virus inactivation/elimination in therapeutic protein concentrates. In Virus Inactivation in Plasma Products, ed. Morgenthaler, J.-J., pp. 34–43. Basel, Karger.Google ScholarPubMed
Mitra, G., Wong, M. F., Mozen, M. M., et al. (1986) Elimination of infectious retroviruses during preparation of immunoglobulins. Transfusion, 26, 394–7.CrossRefGoogle ScholarPubMed
Miyagawa, E., Yoshida, T., Takahashi, H., et al. (1999) Infection of the erythroid cell line, KU812Ep6 with human parvovirus B19 and its application to titration of B19 infectivity. J Virol Methods, 83, 45–54.CrossRefGoogle ScholarPubMed
Mondorf, A. W., Stephan, W., Uthemann, H., et al. (1981) A clinical study of the tolerance and safety of a beta-propiolactone-treated immunoglobulin. Arzneimittel-Forschung, 31, 1928–30.Google ScholarPubMed
Montagnier, L., Chermann, J. C., Barré-Sinoussi, F., et al. (1983) Diagnosis of Lymphadenopathy and Acquired Immune Deficiency Syndrome. US Patent application, No. 558 109.
More, J. E. and Harvey, M. J. (1991) Purification technologies for human plasma albumin. In Blood Separation and Plasma Fractionation, ed. Harris, J. R., pp. 261–306. New York, John Wiley & Sons, Inc.Google Scholar
Morfini, M., Mannucci, P. M., Ciaverella, N., et al. (1994) Prevalence of infection with the hepatitis C virus among Italian hemophiliacs before and after the introduction of virally inactivated clotting factor concentrates: a retrospective evaluation. Vox Sang, 67, 178–82.CrossRefGoogle ScholarPubMed
Morgado, A. F. and da Fonte, J. G. (1979) An outbreak of hepatitis attributable to inoculation with contaminated gamma globulin. Bull Pan Am Health Organ, 13, 177–86.Google ScholarPubMed
Morgan, H. V. and Williamson, D. A. J. (1943) Jaundice following administration of human blood products. BMJ, 1, 750–53.CrossRefGoogle ScholarPubMed
Morgenthaler, J. J., Maring, J. A. and Rentsch, M. (2002) Method for the Removal of Causative Agent(s) of Transmissible Spongiform Encephalopathies from Protein Solutions. USA Patent, No. 6 407 212.
Mortimer, P. P., Jesson, W. J., Vandervelde, E. M., et al. (1985) Prevalence of antibody to human lymphotropic virus type III by risk group and area, United Kingdom 1978–1984. BMJ (Clinical Research Edition), 290, 1176–8.CrossRefGoogle Scholar
Mortimer, P. P., Luban, N. L. C., Kelleher, J. F., et al. (1983) Transmission of parvovirus-like virus by clotting factor concentrates. Lancet, ii, 482–4.CrossRefGoogle Scholar
Mösseler, J., Schimpf, K., Auerswald, G., et al. (1985) Inability of pasteurised factor VIII preparations to induce antibodies to HTLV-III after long-term treatment. Lancet, i, 111.Google Scholar
Murphy, W. P. and Workman, W. G. (1953) Serum hepatitis from pooled irradiated dried plasma. Journal of the American Medical Association, 152, 1421–3.CrossRefGoogle ScholarPubMed
Murray, R. (1955) Viral hepatitis. Bull N Y Acad Med, 31, 341–58.Google ScholarPubMed
Murray, R. and Diefenbach, W. C. L. (1953) Effect of heat on the agent of homologous serum hepatitis. Proceedings of the Society of Experimental Biology and Medicine, 84, 230–1.CrossRefGoogle ScholarPubMed
Murray, R. and Ratner, F. (1953) Safety of immune serum globulin with respect to homologous serum hepatitis. Proceedings of the Society of Experimental Biology and Medicine, 83, 554–5.CrossRefGoogle ScholarPubMed
Murray, R., Diefenbach, W. C., Geller, H., et al. (1955a) The problem of reducing the danger of serum hepatitis from blood and blood products. N Y State J Med, 55, 1145–60.Google Scholar
Murray, R., Oliphant, J. W., Tripp, J. T., et al. (1955b) Effect of ultraviolet radiation on the infectivity of icterogenic plasma. J Am Med Assoc, 157, 8–14.CrossRefGoogle Scholar
Murray, R., Ratner, F., Diefenbach, W. C. L., et al. (1954) Effect of storage at room temperature on infectivity of icterogenic plasma. J Am Med Assoc, 155, 13–5.CrossRefGoogle ScholarPubMed
Mussgay., M. (1964) Studies on the structure of a hemagglutinating component of a group A arbovirus (Sindbis). Virology, 23, 573–81.CrossRefGoogle Scholar
Neurath, A. R., Vernon, S. K., Dobkin, M. B., et al. (1972) Characterization of subviral components resulting from treatment of rabies virus with tri-n-butyl phosphate. J Gen Virol, 14, 33–48.CrossRefGoogle ScholarPubMed
Newman, J., Johnson, A. J., Karpatkin, M. H., et al. (1971) Methods for the production of clinically effective intermediate and high purity factor VIII concentrates. Br J Haematol, 21, 1–20.CrossRefGoogle ScholarPubMed
Ng, P. K. and Dobkin, M. B. (1985) Pasteurisation of antihemophilic factor and model virus inactivation studies. Thromb Res, 39, 439–47.CrossRefGoogle ScholarPubMed
Nilsson, I. M., Blömback, M. and Ramgren, O. (1962) Haemophilia in Sweden. VI. Treatment of haemophilia with the human antihaemophilia factor preparation (fraction I-0). Acta Medica Scandinavia, 379 (Suppl.), 61–110.Google Scholar
Nishizawa, T., Okamoto, H., Konishi, K., et al. (1997) A novel DNA virus (TTV) associated with elevated transaminase levels in post-transfusion hepatitis of unknown etiology. Biochem Biophys Res Commun, 241, 92–7.CrossRefGoogle Scholar
Noble, R. C., Kane, M. A., Reeves, S. A., et al. (1984) Post-transfusion hepatitis A in a neonatal intensive care unit. J Am Med Assoc, 252, 2716–21.CrossRefGoogle Scholar
Noel, L., Guerois, C., Maisonneuve, P., et al. (1989) Antibodies to hepatitis C virus in hemophilia. Lancet, ii, 560.CrossRefGoogle Scholar
Nowak., T., Gregersen, J. P., Klockmann, U., et al. (1992) Virus safety of human immunoglobulins: efficient inactivation of hepatitis C and other human pathogenic viruses by the manufacturing procedure. J Med Virol, 36, 209–16.CrossRefGoogle ScholarPubMed
Nowak, T., Niedrig, M., Bernhardt, D.,et al. (1993) Inactivation of HIV, HBV, HCV related viruses and other viruses in human plasma derivatives by pasteurisation. Dev Biol (Basel), 81, 169–76.Google ScholarPubMed
Nubling, C., Chudy, M. and Lower, J. (1999) Validation of HCV-NAT assays and experience with NAT application for blood screening in Germany. Biologicals, 27, 291–4.CrossRefGoogle ScholarPubMed
Nubling, C., Groner, A. and Lower, J. (1998) GB virus C/hepatitis G virus and intravenous immunoglobulin. Vox Sang, 75, 189–92.CrossRefGoogle Scholar
Nubling, C., Willkommen, H. and Lower, J. (1995) Hepatitis C transmission associated with intravenous immunoglobulins. Lancet, 345, 1174.Google ScholarPubMed
Ochs, H. D., Fischer, S. H., Virant, F. S., et al. (1985) Non-A, non-B hepatitis and intravenous immunoglobulin. Lancet, i, 404–5.CrossRefGoogle Scholar
Ochs, H. D., Fischer, S. H., Virant, F. S., et al. (1986) Non-A, non-B hepatitis after intravenous immunoglobulin. Lancet, i, 322–3.Google Scholar
Offergeld, R.,Faensen, D.,Ritter, S., et al. (2005) Human immunodeficiency virus, hepatitis C and hepatitis B infections among blood donors in Germany 2000–2002: risk of virus transmission and impact of nucleic acid amplification testing. Euro Surveill, 10, 8–11.CrossRefGoogle ScholarPubMed
Office of Biologics Research and Review (1987) Points to Consider in the Manufacture and Testing of Monoclonal Antibody Products for Human Use. Bethesda, MD, Food and Drug Administration.
Oliphant, J. W. and Hollaender, A. (1946) Homologous serum jaundice: experimental inactivation of etiological agent in serum by ultraviolet irradiation. Public Health Rep, 61, 598–602.CrossRefGoogle Scholar
Omar, A. and Kempf, C. (2002) Removal of neutralized model parvoviruses and enteroviruses in human IgG solutions by nanofiltration. Transfusion, 42, 1005–10.CrossRefGoogle ScholarPubMed
Omar, A., Kempf, C., Immelmann, A., et al. (1996) Virus inactivation by pepsin treatment at pH 4 of IgG solutions: factors affecting the rate of virus inactivation. Transfusion, 36, 866–72.CrossRefGoogle ScholarPubMed
Oncley, J. L., Melin, M., Richert, D. A., et al. (1949) The separation of the antibodies, isoagglutinins, prothrombin, plasminogen and β1-lipoprotein into subfractions of human plasma. J Am Chem Soc, 71, 541–50.CrossRefGoogle ScholarPubMed
Onions, D. (2004) Animal virus contaminants of biotechnology products. Dev Biol, 118, 155–63.Google ScholarPubMed
Over, J. (1998) Nanofiltration, the EPFA experience. In Proceedings of Planova® Workshop, Oslo, 27 June 1998, pp. 5–15. Tokyo, Asahi Chemical Industry Co. Ltd.Google Scholar
Paine, R. S. and Janeway, C. A. (1952) Human albumin infusions and homologous serum jaundice. J Am Med Assoc, 150, 199–202.CrossRefGoogle ScholarPubMed
Palmer, J. W. (1976) The evolution of large-scale human plasma fractionation in the United States. In Proceedings of the Workshop on Albumin, eds Sgouris, J. T. and René, A., pp. 255–269. Washington, Department of Health, Education, and Welfare, DHEW Publication No. (NIH) 76–925.Google Scholar
Pasi, K. J., Evans, J. A., Skidmore, S. J.,et al. (1990) Prevention of hepatitis C infection in haemophiliacs. Lancet, 335, 1473–4.CrossRefGoogle Scholar
Patek, A. J. and Taylor, F. H. L. (1937) Hemophilia II. Some properties of a substance obtained from normal plasma effective in accelerating the coagulation of hemophilic blood. J Clin Invest, 16, 113–24.CrossRefGoogle ScholarPubMed
Pattison, C. P., Klein, C. A., Leger, R. T., et al. (1976) An outbreak of type B hepatitis associated with transfusion of plasma protein fraction. Am J Epidemiol, 103, 399–407.CrossRefGoogle ScholarPubMed
Paul-Ehrlich-Institut (1994) Reducing the risk of transmission of haematologenous viruses in medicinal products derived from human plasma by fractionation. Bundesanzeiger, 101, 9243–4.
Payne, W. W. and Steen, R. E. (1929) Haemostatic therapy in haemophilia. BMJ, 1, 1150–2.CrossRefGoogle ScholarPubMed
Peden, A. H., Head, M. W., Ritchie, D. L., et al. (2004) Preclinical vCJD after blood transfusion in a PRNP codon 129 heterozygous patient. Lancet, 364, 529–31.CrossRefGoogle Scholar
Peerlinck, K. and Vermylen, J. (1993) Acute hepatitis A in patients with haemophilia. Lancet, 341, 189.CrossRefGoogle ScholarPubMed
Peerlinck, K., Arnout, J., Giambattista, M. D., et al. (1997) Factor VIII inhibitors in previously treated haemophilia A patients with a double virus-inactivated plasma derived factor VIII concentrate. Thromb Haemost, 77, 80–6.Google ScholarPubMed
Peerlinck, K., Arnout, J., Gilles, J. G., et al. (1993) A higher than expected incidence of factor VIII inhibitors in multi-transfused haemophilia A patients treated with an intermediate purity pasteurised factor VIII concentrate. Thromb Haemost, 69, 115–8.Google Scholar
Peerlinck, K., Goubau, P., Coppens, G., et al. (1994) Is the apparent outbreak of hepatitis A in Belgian haemophiliacs due to a loss of previous passive immunity?Vox Sang, 67 (Suppl. 1), 14–7.CrossRefGoogle Scholar
Pennell, R. B. (1957) The distribution of certain viruses in the fractionation of plasma. In Hepatitis Frontiers, eds Hartman, F. W., LoGrippo, G. A., Mateer, J. G. and Barron, J., pp. 297–309. London, J. & A. Churchill Ltd.Google Scholar
Petrilli, F. L., Crovari, P. and Flora, S. (1977) Hepatitis B in subjects treated with a drug containing immunoglobulins. J Infect Dis, 135, 252–8.CrossRefGoogle ScholarPubMed
Phillips, L. L. (1965) Homologous serum jaundice following fibrinogen administration. Surg Gynecol and Obstet, 121, 551–6.Google ScholarPubMed
Piszkiewicz, D., Andrews, J., Holst, S., et al. (1986a) Safety of immunoglobulin preparations containing antibody to LAV/HTLV-III. In Progress in Immunodeficiency Research and Therapy II, eds Vossen, J. and Griscelli, C., pp. 197–200. Amsterdam, Elsevier.Google Scholar
Piszkiewicz, D., Mankarious, S., Holst, S., et al. (1986b) HIV antibodies in commercial immune globulins. Lancet, i, 1327.CrossRefGoogle Scholar
Piszkiewicz, D., Sun, C. S. and Tondreau, S. C. (1989) Inactivation and removal of human immunodeficiency virus in monoclonal purified antihemophilic factor (human) (Hemofil M). Thromb Res, 55, 627–34.CrossRefGoogle Scholar
Pocchiari, M. (1991) Methodological aspects of the validation of purification procedures of human/animal-derived products to remove unconventional slow viruses. Dev Biol (Basel), 75, 87–95.Google ScholarPubMed
Pollmann, H. and Richter, H. (1994) Prevalence of hepatitis and HIV in a group of haemophiliacs. In Proceedings of the 21st International Congress of the World Federation of Hemophilia, p. 309. Mexico City, World Federation of Hemophilia.Google Scholar
Pool, J. G. and Robinson, J. (1959) Observations on plasma banking and transfusion procedures for haemophilic patients using a quantitative assay for antihaemophilic globulin (AHG). Br J Haematol, 5, 24–30.CrossRefGoogle Scholar
Pool, J. G. and Shannon, A. E. (1965) Production of high-potency concentrates of antihemophilic globulin in a closed-bag system. Assay in vitro and in vivo. N Engl J Med, 273, 1443–7.CrossRefGoogle Scholar
Pool, J. G., Hershgold, E. J. and Pappenhagen, A. R. (1964) High-potency antihaemophilic factor concentrate prepared from cryoglobulin precipitate. Nature, 203, 312.CrossRefGoogle ScholarPubMed
Porter, J. E., Shapiro, M., Maltby, G. L.et al. (1953) Human thrombin as a vehicle of infection in homologous serum hepatitis. J Am Med Assoc, 153, 17–9.CrossRefGoogle ScholarPubMed
Porter, R. R. (1960) γ-Globulins and antibodies. In The Plasma Proteins, volume 1. Isolation, Characterization, and Function, ed. Putnam, F. W., pp. 241–77. New York, Academic Press.Google Scholar
Powell, J. S., Bush, M., Harrison, J., et al. (2000) Safety and efficacy of solvent/detergent-treated antihaemophilic factor with an added 80℃ terminal dry heat treatment in patients with haemophilia A. Haemophilia, 6, 140–9.CrossRefGoogle ScholarPubMed
Power, J. P., Lawlor, E., Davidson, F., et al. (1994) Hepatitis C viraemia in recipients of Irish intravenous anti-D immunoglobulin. Lancet, 344, 1166–7.CrossRefGoogle ScholarPubMed
Preece, M. A. (1986) Creutzfeldt-Jakob disease: implications for growth hormone-deficient children. Neuropathol Appl Neurobiol, 12, 509–15.CrossRefGoogle ScholarPubMed
Prescott, L. E. and Simmonds, P. (1998) Global distribution of transfusion-transmitted virus. N Engl J Med, 339, 776–7.CrossRefGoogle ScholarPubMed
Preston, F. E., Hay, C. R. M., Dewar, M. S., et al. (1985) Non-A, non-B hepatitis and heat-treated factor VIII concentrates. Lancet, ii, 213.CrossRefGoogle Scholar
Prikhod'ko, G. G. (2005) Dry-heat sensitivity of human B19 and porcine parvoviruses. Transfusion, 45, 1692–3.CrossRefGoogle ScholarPubMed
Prince, A. M., Brotman, B., Grady, G. F., et al. (1974) Long-incubation post-transfusion hepatitis without serological evidence of exposure to hepatitis-B virus. Lancet, ii, 241–6.CrossRefGoogle Scholar
Prince, A. M., Horowitz, B. and Brotman, B. (1986) Sterilization of hepatitis and HTLV-III viruses by exposure to tri-n-butyl phosphate and sodium cholate. Lancet, i, 706–10.CrossRefGoogle Scholar
Prince, A. M., Horowitz, B., Brotman, B., et al. (1984) Inactivation of hepatitis B and Hutchinson strain non-A, non-B hepatitis viruses by exposure to Tween 80 and ether. Vox Sang, 46, 36–43.CrossRefGoogle ScholarPubMed
Prince, A. M., Horowitz, B., Dichtelmeuller, H., et al. (1985) Quantitative assays for evaluation of HTLV-III inactivation procedures: tri-n-butyl phosphate: sodium cholate and beta-propiolactone. Cancer Res, 45 (Suppl.), 4592S.Google ScholarPubMed
Propert, S. A. (1938) Hepatitis after prophylactic serum. BMJ, 2, 677–8.CrossRefGoogle Scholar
Prothero, J. L. (1974) Blood fractions for haemophilia. Lancet, ii, 300–1.CrossRefGoogle Scholar
Prowse, C. V., Griffin, B., Pepper, D. S., et al. (1981) Changes in factor VIII complex activities during the production of a clinical intermediate-purity factor VIII concentrate. Thromb Haemost, 46, 597–601.Google ScholarPubMed
Purcell, R. H., Gerin, J. L., Popper, H., et al. (1985) Hepatitis B virus, hepatitis non-A, non-B virus and hepatitis delta virus in lyophilized anti-hemophilia factor: relative sensitivity to heat. Hepatology, 5, 1091–9.CrossRefGoogle Scholar
Rabenau, H., Ohlinger, V., Anderson, J., et al. (1993) Contamination of genetically engineered CHO-cells by epizootic haemorrhagic disease virus (EHDV). Biologicals, 21, 207–14.CrossRefGoogle Scholar
Ramsay, R. B., Palmer, E. L., McDougal, J. S., et al. (1984) Antibody to lymphadenopathy-associated virus in haemophiliacs with and without AIDS. Lancet, ii, 397–8.CrossRefGoogle Scholar
Raut, S., Di Giambattista, M., Bevan, S. A., et al. (1998) Modification of factor VIII in therapeutic concentrates after virus inactivation by solvent-detergent and pasteurisation. Thromb Haemost, 80, 624–31.Google ScholarPubMed
Redeker, A. G., Hopkins, C. E., Jackson, B., et al. (1968) A controlled study of the safety of pooled plasma stored in the liquid state at 30–32 ℃ for six months. Transfusion, 8, 60–64.CrossRefGoogle ScholarPubMed
Reichl, H. E., Foster, P. R., Li, Q., et al. (2002) Studies on the removal of a bovine spongiform encephalopathy-derived agent by processes used in the manufacture of human immunoglobulin. Vox Sang, 83, 137–45.CrossRefGoogle ScholarPubMed
Reid, K. G., Cuthbertson, B., Jones, A. D. L., et al. (1988) Potential contribution of mild pepsin treatment at pH4 to the viral safety of human immunoglobulin products. Vox Sang, 55, 75–80.CrossRefGoogle ScholarPubMed
Remington, K. M., Trejo, S. R., Buczynski, G., et al. (2004) Inactivation of West Nile virus, vaccinia virus and viral surrogates for relevant and emergent viral pathogens in plasma-derived products. Vox Sang, 87, 10–8.CrossRefGoogle ScholarPubMed
Remis, R. S., O'Shaughnessy, M., Tsoukas, C., et al. (1990) HIV transmission to patients with hemophilia by heat-treated donor screened factor concentrate. Can Med Assoc J, 142, 1247–54.Google ScholarPubMed
Ristol, P., Gensana, M., Fernandez, J., et al. (1996) Evaluation of viral safety of a high-purity human factor VIII concentrate submitted to two specific virus inactivation treatments (FANDHI). Sangre (Barcelona), 41, 131–6.Google Scholar
Rizza, C. R., Fletcher, M. L. and Kernoff, P. B. A. (1993) Confirmation of viral safety of dry heated factor VIII concentrate (8Y) prepared by Bio Products Laboratory (BPL): a report on behalf of UK haemophilia centre directors. Br J Haematol, 84, 269–72.CrossRefGoogle Scholar
Rizza, C. R., Spooner, R. J. D. and Giangrande, P. L. F. (2001) Treatment of haemophilia in the United Kingdom 1981–1996. Haemophilia, 7, 349–59.CrossRefGoogle ScholarPubMed
Rizzetto, M., Canese, M. G., Arico, S., et al. (1977) Immunofluorescence detection of a new antigen-antibody system (δ/anti-δ) associated to hepatitis B virus in liver and in serum of HBsAg carriers. Gut, 18, 997–1003.CrossRefGoogle ScholarPubMed
Rizzetto, M., Hoyer, B., Canese, M. G., et al. (1980) δ agent: association of δ antigen with hepatitis B surface antigen and RNA in serum of δ-infected chimpanzees. Proceedings of the National Academy of Sciences USA, 77, 6124–8.CrossRefGoogle ScholarPubMed
Rizzetto, M., Morello, C., Mannucci, P. M., et al. (1982) Delta infection and liver disease in hemophilic carriers of hepatitis B surface antigen. J Infect Dis, 145, 18–22.CrossRefGoogle ScholarPubMed
Roberts, P. (2000) Resistance of vaccinia virus to inactivation by solvent/detergent treatment of blood products. Biologicals, 28, 29–32.CrossRefGoogle ScholarPubMed
Roberts, P. L. and Hart, H. (2000) Comparison of the inactivation of canine and bovine parvoviruses by freeze-drying and dry-heat treatment in two high-purity factor VIII concentrates. Biologicals, 28, 185–8.CrossRefGoogle ScholarPubMed
Roberts, P. L., El Hana, C. and Saldana, J. (2006) Inactivation of parvovirus B19 and model viruses in factor VIII by dry heat treatment at 80 ℃. Transfusion, 46, 1648–50.CrossRefGoogle ScholarPubMed
Roggendorf, M., Deinhardt, F., Rasshofer, R., et al. (1989) Antibodies to hepatitis C virus. Lancet, ii, 324–5.CrossRefGoogle Scholar
Rosenberg, G. Y., Kiselev, A. E., Barinsky, I. F., et al. (1971) On the thermoinactivation of Botkin's hepatitis virus in dry fibrinogen and albumin preparations. In Proceedings of the 12th Congress of the International Society of Blood Transfusion, Moscow 1969, Bibliotheca Haematalogica, No. 38, part II, pp. 474–8. Basel, Karger.Google Scholar
Rosendaal, F. R., Niewenhuis, H. K., Berg, H. M., et al. (1993) A sudden increase in factor VIII inhibitor development in multitransfused haemophilia A patients in the Netherlands. Blood, 81, 2180–6.Google ScholarPubMed
Rosenthal, N., Bassen, F. A. and Michael, S. R. (1950) Probable transmission of viral hepatitis by ultraviolet-irradiated plasma: report of three cases. J Am Med Assoc, 144, 224–6.CrossRefGoogle Scholar
Rosina, F., Saracco, G. and Rizzetto, M. (1985) Risk of post-transfusion infection with the hepatitis delta virus. A multicenter study. N Eng J Med, 312, 1488–91.CrossRefGoogle ScholarPubMed
Rossi, G., Tucci, A., Cariani, E., et al. (1997) Outbreak of hepatitis C virus infection in patients with haematological disorders treated with intravenous immunoglobulin: different prognosis according to immune status. Blood, 90, 1309–14.Google ScholarPubMed
Rotblat, F., O'Brien, D. P., O'Brien, F. J., et al. (1985) Purification of human factor VIII: C and its characterization by Western blotting using monoclonal antibodies. Biochemistry, 24, 4294–300.CrossRefGoogle Scholar
Roussell, R. H. and McCue, J. P. (1991) Antibody purification from plasma. In Blood Separation and Plasma Fractionation, ed. Harris, J. R., pp. 307–40. New York, John Wiley & Sons, Inc.Google Scholar
Rouzioux, C., Brun-Vezinet, F., Courouce, A. M., et al. (1985) Immunoglobulin G antibodies to lymphadenopathy-associated virus in differently treated French and Belgian hemophiliacs. Ann Intern Med, 102, 476–9.CrossRefGoogle ScholarPubMed
Rubinstein, A. (1984) Heat Treatment of Lyophilized Blood Clotting Factor VIII Concentrate. US Patent, No. 4456590.
Rubinstein, A. and Dodds, W. J. (1982) Heat treated lyophilised factor VIII concentrate and factor IX concentrate studies in hemophilia A and B dogs. In Proceedings of the 19th Congress of the International Society of Haematology and the 17th Congress of the International Society of Blood Transfusion, Budapest, 1–7 August 1982, p. 360. Budapest, Akadémiai Nyomda.Google Scholar
Rumi, M. G., Colombo, M., Gringeri, A., et al. (1989) High prevalence of antibody to hepatitis C virus in multitransfused hemophiliacs with normal transaminase levels. Ann Intern Med, 112, 379–80.CrossRefGoogle Scholar
Saldanha, J. and Minor, P. (1996) Detection of human parvovirus B19 DNA in plasma pools and blood products derived from these pools: implications for the efficiency and consistency of removal of B19 DNA during manufacture. Br J Haematol, 93, 714–9.CrossRefGoogle ScholarPubMed
Sarngadharan, M. G., Popovic, M., Bruch, L., et al. (1984) Antibodies reactive with human T-lymphotropic retroviruses (HTLV-III) in the serum of patients with AIDS. Science, 224, 506–8.CrossRefGoogle ScholarPubMed
Savage, M. and Hinskens, W. (1997) Use of Structured Depth Filters for Virus Removal. European Patent Application, No. EP0 798 003.
Savage, M., Torres, J., Franks, L., et al. (1998) Determination of adequate moisture content for efficient dry-heat viral inactivation in lyophilized factor VIII by loss on drying and near infrared spectroscopy. Biologicals, 26, 119–24.CrossRefGoogle ScholarPubMed
Sawyer, W. A., Meyer, K. F., Eaton, M. D., et al. (1944) Jaundice in army personnel in the Western region of the United States and its relation to vaccination against yellow fever (parts II, III and IV). Am J Hyg, 39, 35–107.Google Scholar
Scatchard, G., Strong, L. E., Hughes, W. L., et al. (1945) Chemical clinical and immunological studies on the products of human plasma fractionation. XXVI. The properties of solutions of serum albumin of low salt content. J Clin Invest, 24, 671–9.CrossRefGoogle ScholarPubMed
Scheidler, A., Rokos, K., Reuter, T., et al. (1998) Inactivation of viruses by beta-propiolactone in human cryo poor plasma and IgG concentrates. Biologicals, 26, 135–44.CrossRefGoogle ScholarPubMed
Scheinberg, I. H., Kinney, T. D. and Janeway, C. A. (1947) Homologous serum jaundice. J Am Med Assoc, 134, 841–8.CrossRefGoogle ScholarPubMed
Schimpf, K., Brachmann, H. H., Kreuz, W., et al. (1989) Absence of anti-human immunodeficiency virus types 1 and 2 seroconversion after treatment of hemophilia A and B or von Willebrand's disease with pasteurized factor VIII concentrate. N Eng J Med, 321, 1148–52.CrossRefGoogle ScholarPubMed
Schimpf, K., Mannucci, P. M., Kreuz, W., et al. (1987) Absence of hepatitis after treatment with a pasteurized factor VIII. N Eng J Med, 316, 918–22.CrossRefGoogle ScholarPubMed
Schmidt, I., Blümel, H., Seitz, H., et al. (2001) Parvovirus B19 DNA in plasma pools and plasma derivatives. Vox Sang, 81, 228–35.CrossRefGoogle ScholarPubMed
Schneider, B., Becker, M., Brackmann, H. H., et al. (2004) Contamination of coagulation factor concentrates with human parvovirus B19 genotype 1 and 2. Thromb Haemost, 92, 838–845.Google ScholarPubMed
Schreiber, A. B., Hrindra, M. E., Newman, J., et al. (1989) Removal of viral contaminants by monoclonal antibody purification of plasma proteins. In Virus Inactivation in Plasma Products, ed. Morgenthaler, J.J, pp. 146–153. Basel, Karger.Google ScholarPubMed
Schroeder, D. B. and Mozen, M. M. (1970) Australia antigen distribution during Cohn ethanol fractionation. Science, 168, 1462–4.CrossRefGoogle ScholarPubMed
Schulman, S., Lindgren, A. C., Petrini, P., et al. (1992) Transmission of hepatitis C with pasteurised factor VIII. Lancet, 340, 305–6.CrossRefGoogle ScholarPubMed
Schuurman, R., Steenis, B., Strien, A., et al. (1991) Frequent detection of bovine polyomavirus in commercial batches of calf serum by using the polymerase chain reaction. J Gen Virol, 72, 2739–45.CrossRefGoogle ScholarPubMed
Schwarz, T. F., Roggendorf, M., Hottenräger, B., et al. (1991) Removal of parvovirus B19 from contaminated factor VIII during fractionation. J Med Virol, 35, 28–31.CrossRefGoogle ScholarPubMed
Schwinn, H. (1996) Deposition in Corson vs. Gulf Coast Regional Blood Center, et al., 2 August 1996. New York, Doyle Reporting, Inc.Google Scholar
Schwinn, H., Heimburger, N., Kumpe, G., et al. (1981) Blood Coagulation Factors and Process for their Manufacture. US patent, no. 4297344.
Seeberg, S., Brandberg, A, Hermodsson, S., et al. (1981) Hospital outbreak of hepatitis A secondary to blood exchange in a baby. Lancet, i, 1155–6.CrossRefGoogle Scholar
Seremetis, V. S., Aledort, L. M., Bergman, G. E., et al. (1993) Three-year randomised study of high-purity or intermediate-purity factor VIII concentrates in symptom-free HIV-seropositive haemophiliacs: effects on immune status. Lancet, 342, 700–3.CrossRefGoogle ScholarPubMed
Sergiev, P. G., Tareev, E. M., Gontaeva, A. A., et al. (1940) Virusnaya sheltukha: Epidemicheski gepatit v sviasi s immunizatchiei tchelovetscheskoi syvorotkoi. Terapevticheski Archiv, 18, 595–611.Google Scholar
Sexton, D. J., Rollin, P. E., Breitschwerdt, E. B., et al. (1997) Life-threatening Cache Valley virus infection. N Eng J Med, 336, 547–9.CrossRefGoogle ScholarPubMed
Shepard, C. W., Simard, E. P., Finelli, L., et al. (2006) Hepatitis B virus infection: epidemiology and vaccination. Epidemiologic Rev, 28, 112–25.CrossRefGoogle ScholarPubMed
Sherertz, R. J., Russell, B. A. and Reuman, P. D. (1984) Transmission of hepatitis A by transfusion of blood products. Arch Intern Med, 144, 1579–80.CrossRefGoogle ScholarPubMed
Shikata, T., Karasawa, T., Abe, K., et al. (1978) Incomplete inactivation of hepatitis B virus after heat treatment at 60 ℃ for 10 hours. J Infect Dis, 138, 242–4.CrossRefGoogle ScholarPubMed
Shimizu, Y.K., Feinstone, S. M., Purcell, R. H., et al. (1979) Non-A, non-B hepatitis: ultrastructural evidence for two agents in experimentally infected chimpanzees. Science, 205, 197–200.CrossRefGoogle ScholarPubMed
Shopnick, R. I., Bolivar, E. and Brettler, D. B., et al. (1996) Hepatitis C seropositivity in HIV-negative children with severe haemophilia. Haemophilia, 2, 100–3.CrossRefGoogle ScholarPubMed
Silva, L. C., Sette, H., Antonacio, F., et al. (1977) Commercial gammaglobulin (CGG) as a possible vehicle of transmission of HBsAg in familial clustering. Revista do Instituto de Medicina Tropical de São Paulo, 19, 352–4.Google ScholarPubMed
Silveira, J. A., Raymond, G. J., Hughson, A. G., et al. (2005) The most infectious prion protein particles. Nature, 437, 257–61.CrossRefGoogle ScholarPubMed
Simmonds, P., Davidson, F., Lycett, C., et al. (1998) Detection of a novel DNA virus (TTV) in blood donors and blood products. Lancet, 352, 191–5.CrossRefGoogle ScholarPubMed
Skidmore, S., Boxall, E. and Ala, F. (1982) A case report of post-transfusion hepatitis A. J Med Virol, 10, 223.CrossRefGoogle ScholarPubMed
Skinner, J. S. (1957) Serum hepatitis: occurrence following the use of human fibrinogen. Mo Med, 54, 740–4.Google ScholarPubMed
Smith, D. B., Lawlor, E., Power, J., et al. (1999) A second outbreak of hepatitis C virus infection from anti-D immunoglobulin in Ireland. Vox Sang, 76, 175–8.CrossRefGoogle ScholarPubMed
Smith, M. P., Rice, K. M. and Savidge, G. F. (1997) Successful clinical use of a plasma-derived, dual virus inactivated factor VIII concentrate incorporating solvent-detergent and dry heat treatment. Thromb Haemost, 77, 406–7.Google ScholarPubMed
Snape, T. J. (1987) Quality control in the development of coagulation factor concentrates. Devel Biol (Basel), 67, 141–67. In Viral Hepatitis: Standardization immunoprophylaxis of Infections by Hepatitis Viruses, eds Schiff, P. and Hennessen, W.. Basel, Karger.Google Scholar
Soper, F. L. and Smith, H. H. (1938) Yellow fever vaccination with cultivated virus and immune and hyperimmune serum. Am J Trop Med, 18, 111–34.CrossRefGoogle Scholar
Soucie, J. M., Richardson, L. C., Evatt, B. L., et al. (2001) Risk factors for infection with HBV and HCV in a large cohort of haemophiliac males. Transfusion, 41, 338–43.CrossRefGoogle Scholar
Soulier, J. P., Blatix, C., Courouce, A. M., et al. (1972) Prevention of virus B hepatitis (SH hepatitis). Am J Dis Child, 123, 429–34.Google Scholar
Spire, B., Dormont, D., Barré-Sinoussi, F., et al. (1985) Inactivation of lymphadenopathy-associated virus by heat, gamma rays, and ultraviolet light. Lancet, i, 188–9.CrossRefGoogle Scholar
Spurling, N., Shone, J. and Vaughan, J. (1946) The incidence, incubation period, and symptomatology of homologous serum jaundice. BMJ, 2, 409–12.CrossRefGoogle ScholarPubMed
Stephan, W. (1975) Undegraded human immunoglobulin for intravenous use. Vox Sang, 28, 422–37.CrossRefGoogle ScholarPubMed
Stephan, W. (1989) Inactivation of hepatitis viruses and HIV in plasma and plasma derivatives by treatment with β-propiolactone/UV irradiation. In Virus Inactivation in Plasma Products, ed. Morgenthaler, J. J., pp. 275–36. Basel, Karger.Google ScholarPubMed
Stirling, M. L., Murray, J. A., Mckay, P., et al. (1983) Incidence of infection with hepatitis B virus in 56 patients with haemophilia A 1971–1979. J C Pathol, 36, 577–80.Google ScholarPubMed
Stokes, J., Blanchard, M., Neefe, J. R., et al. (1948) Methods of protection against homologous serum hepatitis SH virus; studies on protective value of gamma-globulin. J Am Med Assoc, 138, 336–41.CrossRefGoogle ScholarPubMed
Strong, L. E. (1948) Blood fractionation. In Encyclopedia of Chemical Technology, volume 2, eds Kirk, R. E. and Othmer, D. F., pp. 1–29. New York, The Interscience Encyclopedia, Inc.Google Scholar
Stucki, M., Moudry, R., Kempf, C., et al. (1997) Characterisation of a chromatographically produced anti-D immunoglobulin product. J Chromatogr, 700, 241–8.CrossRefGoogle ScholarPubMed
Sumazaki, R., Yamada-Osaki, M., Kajiwara, Y., et al. (1998) Transfusion transmitted virus. Lancet, 352, 1308–9.CrossRefGoogle ScholarPubMed
Surgenor, D. M. (2002) Edwin J. Cohn and the Development of Protein Chemistry, p. 221. Boston, Centre for Blood Research, Inc.Google Scholar
Tabor, E. (1999) The epidemiology of virus transmission by plasma derivatives: clinical studies verifying the lack of transmission of hepatitis B and C viruses and HIV type 1. Transfusion, 39, 1160–8.CrossRefGoogle Scholar
Tabor, E. and Gerety, R. J. (1979) Transmission of hepatitis B by immune serum globulin. Lancet, ii, 1293.CrossRefGoogle Scholar
Takahashi, M., Koike, T., Moriyami, Y., et al. (1991) Neutralizing activity of immunoglobulin preparation against erythropoietic suppression of human parvovirus. J Hematol, 37, 68.Google ScholarPubMed
Tateishi, J., Kimoto, T., Ishikawa, G., et al. (1993) Removal of causative agent of Creutzfeldt-Jakob disease (CJD) through membrane filtration method. Membrane, 18, 357–62.CrossRefGoogle Scholar
Tateishi, J., Kimoto, T., Mohri, S., et al. (2001) Scrapie removal using Planova virus removal filters. Biologicals, 29, 17–25.CrossRefGoogle ScholarPubMed
Taylor, D. M. (2003) Inactivation of TSE agents: safety of blood and blood derived products. Transfusion Clinique et Biologique, 10, 23–5.CrossRefGoogle ScholarPubMed
Taylor, F. H. L., Davidson, C. S., Tagnon, H. J., et al. (1945) Studies in blood coagulation: the coagulation properties of certain globulin fractions of normal human plasma in vitro. J Clin Invest, 24, 698–703.CrossRefGoogle ScholarPubMed
Tedder, R. S., Uttley, A. and Cheinsong-Popov, R. (1985) Safety of immunoglobulin preparation containing anti-HTLV-III. Lancet, i, 815.CrossRefGoogle Scholar
Temperley, I. J., Coter, K. P.Walsh, T. J., et al. (1992) Clotting factors and hepatitis A. Lancet, 340, 1466.Google ScholarPubMed
Terpstra, F. G., Parkinen, J., Tola, H., et al. (2006) Viral safety of Nanogam, a new nm-filtered liquid immunoglobulin product. Vox Sang, 90, 21–32.CrossRefGoogle ScholarPubMed
Theiler, M. (1957) Action of sodium desoxycholate on arthropod-borne viruses. The Proceedings of the Society of Experimental Biology and Medicine, 96, 380–2.CrossRefGoogle ScholarPubMed
Thyer, J., Unal, A., Hartel, G., et al. (2006b) Investigation of prion removal/inactivation from chromatographic gel. Vox Sang, 91, 301–8.CrossRefGoogle Scholar
Thyer, J., Unal, A., Thomas, P., et al. (2006a) Prion-removal capacity of chromatographic and ethanol precipitation steps used in the production of albumin and immunoglobulin. Vox Sang, 91, 292–300.CrossRefGoogle Scholar
Torchin, N. G. (1987) Patent Interference No. 101 574 17 September 1987. Washington, US Department of Commerce, Patent and Trade Mark Office.
Trejo, S. R., Hotta, J. A., Lebing, W., et al. (2003) Evaluation of virus and prion reduction in a new intravenous immunoglobulin manufacturing process. Vox Sang, 84, 176–87.CrossRefGoogle Scholar
Trepo, C., Hantz, O., Jacquier, M. F., et al. (1978) Different fates of hepatitis B virus markers during plasma fractionation. A clue to infectivity of blood derivatives. Vox Sang, 35, 143–8.CrossRef
Troccoli, N. M., McIver, J., Losikoff, A., et al. (1998) Removal of viruses from human intravenous immunoglobulin by 35 nm nanofiltration. Biologicals, 26, 321–9.CrossRefGoogle ScholarPubMed
Trump, J. G. and Wright, K. A. (1957) Inactivation of the hepatitis virus by high energy electrons. In Hepatitis Frontiers, eds. Hartman, F. W., LoGrippo, G. A., Mateer, J. G. and Barron, J., pp. 333–41. London, J. & A. Churchill Ltd.Google Scholar
Uemura, Y., Yang, Y. H. L., Heldebrant, C. M., et al. (1994) Inactivation and elimination of viruses during preparation of human intravenous immunoglobulin. Vox Sang, 67, 246–54.CrossRefGoogle ScholarPubMed
UK Regional Haemophilia Centre Directors (1992) Recommendations on choice of therapeutic products for the treatment of patients with haemophilia A, haemophilia B and von Willebrand's disease. Blood Coagul Fibrinolysis, 3, 205–14.CrossRef
Unal, A., Thyer, J., Uren, E., et al. (2007) Investigation by bioassay of the efficacy of sodium hydroxide treatment on the inactivation of mouse-adapted scrapie. Biologicals, 35, 161–4.CrossRefGoogle ScholarPubMed
Holten, R. W. and Autenrieth, S. M. (2003) Evaluation of depth filtration to remove prion challenge from immune globulin preparation, Vox Sang, 85, 20–4.CrossRefGoogle ScholarPubMed
Holten, , Ciavarella, R. W., , D., Oulundsen, G., et al. (2002) Incorporation of an additional viral-clearance step into a human immunoglobulin manufacturing process. Vox Sang, 83, 227–33.CrossRefGoogle ScholarPubMed
Vey, M., Baron, H., Weimer, T., et al. (2002) Purity of spiking agents affects partitioning of prions in plasma protein purification. Biologicals, 30, 187–96.CrossRefGoogle ScholarPubMed
Wagner, R. H. (1967) Report of the sub-committee on human factor VIII (AHF) preparations. Thrombosis Diathesis Haemorrhagica, 26 (Suppl.), 371–5.Google Scholar
Wagner, R. H., Roberts, H. R., Webster, W. P., et al. (1968) Glycine-precipitated antihemophilic factor concentrates and their clinical uses. Thromb Diath Haemorrh, 35 (Suppl.), 41–8.Google Scholar
Wain-Hobson, S., Vartanian, J. P., Henry, M., et al. (1991) LAV revisited: origins of early HIV-1 isolates from Institute Pasteur. Science, 252, 961–5.CrossRefGoogle Scholar
Wang, J., Horner, G. W. and O'Keefe, J. S. (2004) Detection and molecular characterisation of bovine polyomavirus in bovine sera in New Zealand. N Z Vet J, 53, 26–30.CrossRefGoogle Scholar
Watanabe, K. K., Busch, M. P., Schreiber, G. B., et al. (2000) Evaluation of the safety of Rh immunoglobulin by monitoring viral markers among Rh-negative female blood donors. Vox Sang, 78, 1–6.CrossRefGoogle ScholarPubMed
Watson, H. G. and Ludlam, C. A. (1992) Immunological abnormalities in haemophiliacs. Blood Rev, 6, 26–33.CrossRefGoogle ScholarPubMed
Webster, A. D. B., Dalgleish, A. G., Malkovsky, M., et al. (1986) Isolation of retroviruses from two patients with ‘common variable’ hypogammaglobulinaemia. Lancet, i, 581–3.CrossRefGoogle Scholar
Webster, W. P., Roberts, H. R., Thelin, G. M., et al. (1965) Clinical use of a new glycine-precipitated antihemophilic fraction. Am J Med Sci, 250, 643–51.CrossRefGoogle ScholarPubMed
Weiland, O., Mattsson, L. and Glaumann, H. (1986) Non-A, non-B hepatitis after intravenous gamma globulin. Lancet, i, 976–7.CrossRefGoogle Scholar
Weisser, J. (1988) Transmission of human immunodeficiency virus by a dry heat treated factor VIII concentrate. Klinische Pediatrie, 200, 307–9.Google ScholarPubMed
Welch, A. G., Cuthbertson, B., McIntosh, R. V., et al. (1983b) Non-A, non-B hepatitis from intravenous immunoglobulin. Lancet, ii, 1198–9.CrossRefGoogle Scholar
Welch, A. G., McIntosh, R. V. and Foster, P. R. (1983a) Human immunoglobulin for clinical use. Lancet, i, 358.Google Scholar
Welch, J., Bienek, C., Gomperts, E., et al. (2006) Resistance of porcine circovirus and chicken anemia virus to virus inactivation procedures used for blood products. Transfusion, 46, 1951–8.CrossRefGoogle ScholarPubMed
Wells, M. A., Wittek, A. E., Epstein, J. S., et al. (1986) Inactivation and partitioning of human T-cell lymphotropic virus, type III, during ethanol fractionation of plasma. Transfusion, 26, 210–3.CrossRefGoogle Scholar
White, G. C., Matthews, T. J., Weinhold, K. J., et al. (1986) HTLV-III seroconversion associated with heat-treated factor VIII concentrate. Lancet, i, 611–2.CrossRefGoogle Scholar
Whittaker, J. A. and Brown, M. J. (1969) Serum hepatitis in a haemophiliac. BMJ, 3, 597.CrossRefGoogle Scholar
Widell, A., Zhang, Y. Y., Andersson-Gare, B., et al. (1997) At least three hepatitis C virus strains implicated in Swedish and Danish patients with intravenous immunoglobulin-associated hepatitis C. Transfusion, 37, 313–20.CrossRefGoogle ScholarPubMed
Wiese, M., Grüngreiff, K., Güthoff, W., et al. (2005) Outcome in a hepatitis C (genotype 1b) single source outbreak in Germany – a 25-year multicenter study. Journal of Hepatology, 43, 590–8.CrossRefGoogle Scholar
Will, R. G., Ironside, J. W., Zeilder, M., et al. (1996) A new variant of Creutzfeldt-Jakob disease in the UK. Lancet, 347, 921–5.CrossRefGoogle ScholarPubMed
Williams, M. Cohen, D., Beddal, B. J., , A. C., et al. (1990b) Transmission of human parvovirus B19 by coagulation factor concentrates. Vox Sang, 58, 177–81.CrossRefGoogle Scholar
Williams, M. D., Skidmore, S. J. and Hill, F. G. H. (1990a) HIV seroconversion in haemophilic boys receiving heat treated factor VIII concentrate. Vox Sang, 58, 135–6.CrossRefGoogle Scholar
Williams, P. E., Yap, P. L., Gillon, J., et al. (1989) Transmission of non-A, non-B hepatitis by pH4-treated intravenous immunoglobulin. Vox Sang, 57, 15–8.CrossRefGoogle ScholarPubMed
Winkelman, L. (1988) Purification of Blood Coagulation Factor VIII by Precipitation with Sulfated Polysaccharides. US Patent, No. 4 789 733.
Winkelman, L., Owen, N. E., Evans, D. R., et al. (1989) Severely heated therapeutic factor VIII concentrate of high specific activity. Vox Sang, 57, 97–103.CrossRefGoogle ScholarPubMed
Winkelman, L., Owen, N. E., Haddon, M. E., et al. (1985) Treatment of a new, high, specific activity, factor VIII concentrate to inactivate viruses. Thromb Haemost. 54, 19.Google Scholar
Wolf, A. M., Mason, J., Fitzpatrick, W. J., et al. (1947) Ultraviolet irradiation of human plasma to control homologous serum jaundice. J Am Med Assoc, 135, 476–7.CrossRefGoogle ScholarPubMed
Wolfs, T. F., Breederveld, C., Krone, W. J., et al. (1988) HIV-antibody seroconversions in Dutch haemophiliacs using heat-treated and non-heat-treated coagulation factor concentrates. Thromb Haemost, 59, 396–9.Google ScholarPubMed
Wong-Staal, F., Ratner, L., Shaw, G., et al. (1985) Molecular biology of human T-lymphotropic retroviruses. Cancer Research, 45 (9 Suppl.), 4539–44S.Google ScholarPubMed
World Health Organization (1966) The use of human immunoglobulin. Report of a WHO Expert Committee. World Health Organization Technical Report Series, No. 327. Geneva, World Health Organization.
World Health Organization (1971) Prevention of Rh sensitisation. Report of a WHO scientific group. World Health Organization Technical Report Series, No. 468. Geneva, World Health Organization.
World Health Organization (2005) WHO recommendations on the production, control and regulation of human plasma for fractionation. 56th Meeting of the WHO Expert Committee on Biological Standardization. Geneva, World Health Organization.
Wroe, S. J., Pal, S., Siddique, D., et al. (2006) Clinical presentation and pre-mortem diagnosis of variant Creutzfeldt-Jakob disease associated with blood transfusion: a case report. Lancet, 368, 2061–7.CrossRefGoogle ScholarPubMed
Wu, C. G., Mason, B., Jong, J., et al. (2005) Parvovirus transmission by a high-purity factor VIII concentrate. Transfusion, 45, 1003–10.CrossRefGoogle ScholarPubMed
Yamada-Osaki, M., Sumazaki, R. and Kajiwara, Y. (1998) Natural course of HGV in haemophiliacs. Br J Haematol, 102, 616–21.CrossRefGoogle ScholarPubMed
Yap, P. L. (1996) The viral safety of intravenous immunoglobulin. Clin Expl Immunol, 104 (Suppl. 1), 35–42.Google Scholar
Yei, S., Yu, M. W. and Tankersley, D. L. (1992) Partitioning of hepatitis C virus during Cohn-Oncley fractionation of plasma. Transfusion, 32, 824–8.CrossRefGoogle ScholarPubMed
Yokoyama, T., Murai, K., Wakisaka, A., et al. (2004) Removal of small non-enveloped viruses by nanofiltration. Vox Sang, 86, 225–9.CrossRefGoogle ScholarPubMed
Yu, M. W., Mason, B. L., Guo, Z. P., et al. (1995) Hepatitis C transmission associated with intravenous immunoglobulins. Lancet, 345, 1173–4.CrossRefGoogle ScholarPubMed
Yu, M. Y. (1996) Follow-up studies of hepatitis C association with an intravenous immunoglobulin. In Developments in Biological Standardization, 88, pp. 215–6. Basel, Karger.Google Scholar
Yu, M. Y., Bartosch, B., Zhang, P., et al. (2004) Neutralizing antibodies to hepatitis C virus (HCV) in immune globulins derived from anti-HCV-positive plasma. Proceedings of the National Academy of Sciences, 101, 7705–10.CrossRefGoogle ScholarPubMed
Yu, M. Y., Mason, B. L. and Tankersley, D. L. (1994) Detection and characterization of hepatitis C virus RNA in immune globulins. Transfusion, 34, 596–602.CrossRefGoogle ScholarPubMed
Yunoki, M., Urayama, T. and Kuta, K. (2006) Possible removal of prion agents from blood products during the manufacturing process. Future Virology, 1, 659–74.CrossRefGoogle Scholar
Yunoki, M., Urayama, T., Yamamoto, I., et al. (2004) Heat sensitivity of a SARS-associated coronavirus introduced into plasma products. Vox Sang, 87, 302–3.CrossRefGoogle ScholarPubMed
Zanetti, A. R., Ferroni, P., Colombo, M., et al. (1985) Anti-LAV/HTLV-III antibodies in groups of individuals at high risk of infection in Italy. La Ricera in Clinica e in Laboratorio, 15, 357–64.Google ScholarPubMed
Zuckerman, A. J. (1975) Human Viral Hepatitis, 2nd edn. Amsterdam, North-Holland Publishing Company.Google Scholar

Save book to Kindle

To save this book to your Kindle, first ensure [email protected] is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

  • Fractionated products
    • By Peter R. Foster, Protein Fractionation Centre, Scottish National Blood Transfusion Service, Edinburgh, UK, Carol Bienek, Protein Frachianation Centre, Scotish National Blood Transfusion Service, Edinburgh, UK
  • Edited by John A. J. Barbara, University of the West of England, Bristol, Fiona A. M. Regan, Marcela Contreras, University of the West of England, Bristol
  • Book: Transfusion Microbiology
  • Online publication: 12 January 2010
  • Chapter DOI: https://doi.org/10.1017/CBO9780511545245.024
Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

  • Fractionated products
    • By Peter R. Foster, Protein Fractionation Centre, Scottish National Blood Transfusion Service, Edinburgh, UK, Carol Bienek, Protein Frachianation Centre, Scotish National Blood Transfusion Service, Edinburgh, UK
  • Edited by John A. J. Barbara, University of the West of England, Bristol, Fiona A. M. Regan, Marcela Contreras, University of the West of England, Bristol
  • Book: Transfusion Microbiology
  • Online publication: 12 January 2010
  • Chapter DOI: https://doi.org/10.1017/CBO9780511545245.024
Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

  • Fractionated products
    • By Peter R. Foster, Protein Fractionation Centre, Scottish National Blood Transfusion Service, Edinburgh, UK, Carol Bienek, Protein Frachianation Centre, Scotish National Blood Transfusion Service, Edinburgh, UK
  • Edited by John A. J. Barbara, University of the West of England, Bristol, Fiona A. M. Regan, Marcela Contreras, University of the West of England, Bristol
  • Book: Transfusion Microbiology
  • Online publication: 12 January 2010
  • Chapter DOI: https://doi.org/10.1017/CBO9780511545245.024
Available formats
×